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PREFACE
Cardiovascular disease is the leading cause of morbidity and mortality in U.S.
women. Cardiovascular risk screening is recommended for asymptomatic women by
both national and international cardiovascular experts. This EBP project provides
compelling evidence that asymptomatic women exhibit a number of modifiable risk
factors. Such evidence is crucial to demonstrate the imperativeness of primary
prevention initiatives in the clinical practice setting.
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ABSTRACT
Cardiovascular disease (CVD) has long been recognized as a significant health problem
in the U.S., and is the leading cause of preventable death in women, collectively causing
about one death per minute (Caboral, 2013). A myriad of modifiable risk factors including
dyslipidemia, hypertension, smoking, obesity, and type II diabetes are associated with
80-90% of CVD morbidity and mortality. Despite sobering statistics, valid risk prediction
screening tools, and national preventive guidelines, adequate screening in clinical
practice settings is sadly deficient. An evidence-based practice project was designed
and implemented at a large OB/GYN practice in southern Ohio to address this identified
gap in clinical practice. Pender’s health promotion model and Stetler’s evidence-based
practice model provided the theoretical foundation for the project. A critical appraisal of
current evidence was executed to identify best practice recommendations. The literature
was salient in articulating that CVD risk assessment in asymptomatic women was
imperative to guide primary prevention interventions, improves patient outcomes, and
reduce the economic burden of CVD. Synthesis of the literature supported the use of the
Framingham risk score (FRS) model as a gold standard recommendation in the clinical
practice setting. The FRS model was applied to a convenience sample of asymptomatic
women between the ages of 35-50 who presented for their annual gynecologic exam.
Statistical analysis using the SPSS 20 statistical software of the gleaned metrics
demonstrated 91% of the project participants with at least one modifiable CVD risk
factor. 50.5% (n=55) of the EBP project participants had significant CVD risk factors that
necessitated a timely follow up appointment. Using Pearson’s r there were 27
statistically significant relational correlations discerned from the data analysis. The
findings garnered from the EBP project were commensurate with the findings reported in
the scientific literature. The data analysis provided compelling evidence to support the
need for CVD risk screening in asymptomatic women. The literature is salient in
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elucidating anywhere from 25-46% of women consider their gynecologist as their PCP,
therefore, the OB/GYN practice setting is a paramount clinical site for implementation of
CVD risk screening.
Keywords: cardiovascular disease (CVD), modifiable risk factors, screening, risk
prediction models, evidence-based practice, women
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CHAPTER 1
INTRODUCTION
Background
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in
the United States (U.S.). A disease that has traditionally been considered a man’s
disease is dispelled by statistical data acknowledging that as of 2008, more women in
the U.S. died from CVD than from all forms of cancer, respiratory disease, and
Alzheimer’s combined, accounting for one of every three deaths but rapidly approaching
one of every two deaths (Caboral, 2013). Also, since 1984 the number of CVD deaths
for women has consistently exceeded those for men (Moran & Walsh, 2013). In 2007,
CVD caused approximately one death per minute among women in the U.S. (Caboral,
2013). More than 60% of women who died suddenly of CVD had no previous symptoms
of CVD (Wood & Gordon, 2012).
In asymptomatic women, CVD risk is the additive effect of multiple interacting risk
factors. Although data indicate an increased cardiovascular mortality in older women, a
disturbing trend is being observed in young women ages 35-54 (Arslanian-Engoren,
2011). CVD mortality in this age group has increased 1.3% annually since 1997
(Arslanian-Engoren, 2011).These sobering statistics reiterate the necessity of primary
prevention screening and early intervention in women of all ages.
CVD is an enormous economic burden accounting for 17% of national health
expenditures equating to a total of $503 billion in 2010 compared to $228 billion for
cancer (Owen & Reid, 2013). Between 2010 and 2030, real total direct costs of CVD are
projected to reach $818 billion (Owen & Reid, 2013).
Misperceptions remain pervasive both in the patient population and the medical
community regarding the significance of CVD in women. A 2009 cross sectional study of
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2,300 women in the U.S., revealed that only 54% of respondents recognized CVD as
being the leading cause of death in their gender (Caboral, 2013). This lack of awareness
is even more poignant in Central Ohio as elucidated by Gulati and Torkos (2011) whose
survey conducted through Ohio State University revealed that only 22% of Ohio women
understood the dangers of heart disease. While approximately 75% of the surveyed
women had CVD risk factors, only 25% identified themselves at risk for CVD. The
American Heart Association (AHA) released its 2020 Impact Goal of improving the
cardiovascular health of all American’s by 20% and reducing death from CVD by 20% by
the year 2020 (Lloyd-Jones, Hong, Labarthe, Mozaffarian, Appel, Van Horn, Greenlund,
et al., 2010). The AHA has a triad of recommendations to meet their objective which
includes focusing on prevention at all levels of risk, cognizance that risk factors develop
early in life, and providing health promotion and disease prevention at both the
population and individual levels (Heidenreich, 2011). Evidence exists that prevention
works, specifically that >50% of reduction in CVD mortality is due to changes in risk
factors and 40% to improved treatments (Perk, DeBaker, Gohlke, Graham, Reiner,
Verschuren, Albus, et al. 2012).
Multiple barriers to assessment of CVD risk factors in women have been
identified in the literature. Lack of access to care and lack of knowledge and skill in
guideline implementation among internists, family practitioners, and gynecologists are
among the barriers identified. For instance, in a study evaluating the impediments in
CVD prevention, one half of obstetricians-gynecologists and one third of internists
surveyed were unaware that tobacco use is the leading cause of myocardial infarction
(MI) in younger women (Mosca, Benjamin, Berra, Bezanson, Dolor, Lloyd-Jones,
Newby, et al., 2011).
A myriad of risk factors interact synergistically to increase the level of CVD risk.
The majority of these risk factors are modifiable such as dyslipidemia, body mass index
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(BMI), blood pressure, smoking, nutrition, and inactivity. Non-modifiable risk factors
include age, sex, ethnicity, and family history. CVD risk factor modification targeting
lifestyle behaviors (smoking, sedentary lifestyle, poor diet) and comorbid conditions
(hypertension, dyslipidemia, diabetes, and obesity) have the propensity to profoundly
impact CVD burden.
According to the AHA (2012), 53.8 million women have total blood cholesterol
(TC) levels of ≥ 200 mg/dL (Moran & Walsh, 2013). Dyslipidemia as a cardiovascular
risk factor affects women differently than men. Elevated triglycerides (TG) (>200 mg/dL)
and low levels of high-density lipoprotein (HDL) cholesterol (<40 mg/dL) are more potent
independent risk factors for women than for men (Edwards, 2012). A meta-analysis of 17
population based prospective trials demonstrated an 88 mg/dL increase in plasma
triglyceride levels was associated with an increase in relative risk of CVD of 75% in
women compared to 30% in men (Edwards, 2012).
An ominous trend of rising obesity rates now affects nearly two of every three
American women ≥ 20 years of age (Mosca et al., 2011). Overweight or obese as
defined as a BMI of ≥ 25.0 kg/m² affects 71.3 million women above the age of 20 (Moran
& Walsh, 2013). In the United States, 66% of Americans are now considered overweight
or obese (Gleeson & Crabbe, 2009). Obesity, especially central adiposity, is recognized
as one of the most important modifiable cardiovascular risk factors. Based on population
studies risk estimates indicate at least two thirds of the prevalence of hypertension can
be directly attributed to obesity (Chrostowska, Szyndler, Hoffmann, & Narkiewicz, 2013).
In men, the attributable risk of hypertension induced by abdominal obesity ranges from
21% to 27% whereas in women the range is 37% to 57% (Chrostowska, Szyndler,
Hoffmann, & Narkiewicz, 2013). Among individuals in the Framingham Heart Study,
obesity increased the relative risk of CVD by 64% in women (Sharma & Gulati, 2013). In
addition to the direct health consequences of obesity, medical expenditures attributed to
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adult obesity totaled $147 billion in 2008 and are predicted to be greater than $300
billion by 2018 (Shaw, Caughey, & Edelman, 2012). Obesity and adipose tissue itself
have direct and deleterious effects on cardiovascular function and structure. Not only is
obesity an independent risk factor for CVD and hypertension but it also contributes to
dyslipidemia, and Type II diabetes.
Hypertension is an important causative factor in the lifetime risk for developing
heart failure with a reported risk of one in six for women without prior history (Gleeson &
Crabbe, 2009). The evidence linking untreated hypertension to increased cardiovascular
morbidity and mortality is undisputed. In terms of attributable death, the current leading
cause of CVD risk and mortality is elevated blood pressure. A large systematic review of
147 trial reports on the management of hypertension has shown that a mere reduction of
10 mm Hg in systolic blood pressure and 5 mm Hg in diastolic blood pressure was
associated with a 20% reduction in CVD and 32% reduction in stroke in one year (AlAnsary, Tricco, Adi, Bawazeer, Perrier, Al-Ghonaim, AlYousefi, et al., 2013). Elevated
blood pressure contributes to 7.6 million worldwide premature deaths annually (Turnbull,
Kengne, & MacMahan, 2010).
Smoking has an associative affect in a plethora of diseases and is responsible
for 50% of all avoidable deaths in smokers, half of these due to CVD (Perk, DeBacker,
Gohlke, Graham, Reiner, Verschuren, Albus, et al., 2012). Smoking is known to cause
inflammation and thrombotic activity with epidemiologic evidence supporting a dose
relationship between the number of cigarettes smoked and resultant CVD risk. Reports
by the U.S. surgeon general conclude that smoking is the single greatest cause of
avoidable morbidity and mortality in the U.S. (Filion & Guepker, 2013). In women under
the age of 50, cigarette smoking significantly increases the risk for a first MI compared to
men (Gleeson & Crabbe, 2009). 23% of women who have an MI in their 40’s will die
within one year of the cardiovascular event (Johnson & Seibert, 2011). The

SCREENING CARDIOVASCULAR RISK

5

INTERHEART study found that the risk for MI increased by 5.6% for every additional
cigarette smoked per day (Owen & Reid, 2013). Smoking also negatively interacts with
several other CVD risk factors such as hypertension, dyslipidemia, and diabetes.
A Cochrane systematic review found that smoking cessation was associated with
a significant (36%; odds ratio (OR) =0.64, confidence interval (CI) 95%) reduction in risk
of all-cause mortality in patients with CVD (Katskiki, Papadopoulou, Fachantidou, &
Mikhailidis, 2013). Smoking cessation is an effective CVD prevention strategy; within
three years of quitting, risk of MI in the INTERHEART Study had halved (Owen & Reid,
2013). Despite these pervasive statistics, 18.1% of all women in the U.S. continue to
smoke (Wood & Gordon, 2012).
Type II diabetes is another significant risk factor for the development of CVD.
According to the Centers for Disease Control and Prevention (CDC), 11.5 million women
ages 20 and older have diabetes. CVD death rates are increased three to fourfold in
women with diabetes compared to men (Arslanian-Engoren, 2011). Diabetes
accelerates the atherosclerotic process which is commensurate with increasing a
person’s age by approximately 15 years (Worrall-Carter, Ski, Scruth, Campbell & Page,
2011). Type II diabetes is a completely preventable disease which can be averted
through weight management, nutrition, and physical activity.
Physical inactivity is yet another modifiable CVD risk factor. Only about 31% of
American women age 18 and older engage in 30 minutes of moderate physical activity
five times per week as recommended by the AHA (Arslanian-Engoren, 2011). There is
limited randomized data on the independent effects of exercise on the primary
prevention of CVD events, however multiple prospective and retrospective observational
studies have shown that regular exercise is associated with lower rates of CVD (Hsu,
Van-Khue, Ashen, Martin, Gluckman, Kohli, Sisson, et al., 2013). The inverse
relationship between physical activity and risk for developing CVD is present in both men
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and women but is more pronounced in women. The median CVD risk reduction in
women was 40% when most active (30 minutes per day) women were compared to least
active women, whereas that in men was 30% (Shiroma & I-Min, 2010).
In summary, each identified cardiovascular risk is significant in and of itself but
when multiple risk factors are present, the risk exponentially increases. This further
validates the importance of obtaining a complete CVD risk assessment on asymptomatic
women in the clinical setting.
Statement of the problem
The problem that the evidence-based practice project addressed was CVD risk
identification and stratification in asymptomatic women. The rationale for using a risk
prediction model is that in the majority of adults, CVD is the product of greater than one
risk factor; it is the synergistic effect of multiple risk factors over time. The majority of
CVD, (80-90%) is modifiable, but unless women are being screened for CVD risk,
interventions on lifestyle modification cannot be initiated. Mosca, Benjamin, Berra,
Bezanson, Dolor, Lloyd-Jones, Newby, et al., (2011) found that in the three years after
distribution of guideline recommendations for use of the Framingham-based risk scoring,
less than 50% of primary care physicians were implementing them. The aim of CVD risk
assessment is to be more effective in identifying those at risk and to facilitate evidencebased prevention and treatment based modalities.
Over the past 20 years, studies have shown that women are less likely than men
to be evaluated for CVD risk factors. Despite reliable CVD risk screening tools, there is a
prevalent disconnect between what is recommended for risk assessment and the reality
of what is being done in clinical practice. It is the responsibility of the practicing clinician,
in providing comprehensive care, to perform CVD risk assessment on asymptomatic
patients.
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Data from the literature supporting the need for the project
An amalgamation of numerous large-scale clinical trials and systematic reviews
has informed our understanding of cardiovascular risk factors and disease. The
“Effectiveness-Based Guidelines for the Prevention of Coronary Artery Disease in
Women-2011 Update” recommends risk-stratifying women based on their risk scores
into three categories: 1) high risk; 2) at risk; and 3) optimal risk (Sharma & Gulati, 2013).
As has been previously articulated, a handful of modifiable risk factors account for 8090% of CVD. Optimization of these easily measured and potentially modifiable risk
factors could result in a 90% reduction in risk for an initial MI (Berger, Jordan, LloydJones & Blumenthal, 2009).
CVD death rates had been declining between 2000 and 2008 largely due to
advancements in secondary prevention (47%) and risk factor reduction (50%) (Perk et
al., 2012). These statistics support CVD risk factor modification to be profound in
reducing future CVD events in women. However, increasing obesity rates and greater
prevalence of diabetes has reversed the downward trend and has demonstrated
increasing annual CVD death rates of 8% and 10% respectively (Ehrenthal et al., 2011).
Given the social burden of premature death, disability from CVD, and escalating
costs of CVD, there must be a paradigm shift in the approach to cardiac care from
treatment of single risk factors in isolation and opportunistic screening to systematic
screening and to the management of total cardiovascular risk. Risk assessment through
a validated predictive tool and management of CVD risk factors has been recommended
both nationally and internationally by experts in the field as a prudent primary prevention
strategy.
A recent study was conducted by the Cardiovascular Research Foundation
(CRF) in ten OB/GYN offices which assessed 2,234 asymptomatic middle aged women
for CVD risk factors. The results were astonishing; 87% of the women had CVD risk
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factors while 42% had cardiovascular symptoms (Jancin, 2012). Of the women screened
14% had hypertension, 21% were dyslipidemic, and 7.5% had diabetes. Of the
participants assessed, 18% of the participants identified their gynecologist as their
primary care provider while 6% identified no primary care provider at all (Jancin, 2012).
In a review authored by Scholle & Kelleher (2003) 38% of the respondents identified
their gynecologist as their primary care provider. A screening pilot program conducted by
SCAI-Women in Intervention (2012) garnered cardiovascular risk factor data on over
3000 women visiting their OB/GYN office. Over 70 percent of the women screened at 16
study sites had CVD risk factors while 40 percent of them were actually experiencing
cardiovascular symptoms. This study also touted the significant percentage of women
who cite their OB/GYN as their primary care provider.
Improving cardiovascular health of all Americans is a national priority with a goal
of reducing CVD morbidity and mortality and decreasing health care financial
expenditures. The OB/GYN as an identified practice setting must embrace the national
recommended guidelines for CVD risk assessment in asymptomatic women as an
initiative to reduce cardiovascular burden and improve the health of women in the U.S.
A great number of CVD prevention guidelines and tools are reported in the
literature and proclaimed by various national and international organizations as being
superior to another. However, the ultimate objective of all CVD screening guidelines is
identical: to facilitate the prevention of CVD and all its clinical manifestations (De Backer,
Catapano, Chapman, Graham, Reiner, Perk, & Wiklund, 2013). Guidelines should be
simplistic, straightforward, and credible, applicable to the patient population, and be an
aide for informed decision making between the provider and the patient.
The FRS, developed through the Framingham Heart Study (1971-1974), is one
of the earliest and best known epidemiological studies in the field of cardiovascular
disease. The FRS is the most commonly recommended assessment tool for evaluating
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the risk stratification of CVD in the U.S. (Setayeshgar, Whiting, & Vatanparast, 2013).
The critically appraised literature repeatedly recommended the FRS as the gold
standard for evaluating risk and differentiating high-risk from low-risk women. Key
cardiovascular risk factors from the identified Evidence based practice (EBP) project
study population was inputted into the web-based FRS prediction equation for numerical
probability that the individual will develop CVD over a specific time period, generally a
ten year time frame. Additionally, the FRS provided a vascular heart age based on the
gleaned metrics for further informing. Further discussion of the FRS will be detailed in
the method section of chapter three.
Data from the clinical setting supporting the need for the project
It is essential in clinical practice to be able to assess cardiovascular risk
precipitously and with sufficient accuracy to allow logical management decisions.
Lifestages Center’s for Women is a large multi-site OB/GYN practice located in Southern
Ohio and served as the EBP project implementation venue. The mission statement of
Lifestages includes a commitment to providing health and wellness services to women of
all ages. Lifestages recognizes its responsibility to the community, to not only advocate
for, but to develop and implement quality, comprehensive, and cost effective health care
programs which educate, inform and support women in making their health care choices
and living healthful lives. The provider staff of Lifestages includes OB/GYN physicians,
certified nurse midwives (CNM), and a board certified family nurse practitioner (FNP).
The Samaritan north practice site served as the implementation site for the EBP
project and sees on average a hundred women per day. Traditionally the OB/GYN
practice setting has focused on reproductive and gynecologic health not on
cardiovascular health; however as previously elucidated, 25%-46% of women consider
their OB/GYN as their primary care provider (PCP). Sadly, as presented by Mosca et al,
(2011) only one in five physicians knew that more women than men die each year from
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CVD and interestingly, OB/GYN physicians were reported to have substantially less
awareness of national risk assessment guidelines compared to other physicians. Based
on the reported literature, these statistics are detrimental to a woman’s health and the
provider group at Lifestages has collectively agreed to become proactive in reversing
this ominous trend.
Effective nurse leaders are essential to play key roles in shaping the health care
delivery system and addressing primary prevention measures of risk assessment and
intervention modalities for modifiable CVD risk factors. As a family nurse practitioner
(FNP), this Doctor of Nursing Practice (DNP) project manager will be instrumental in
assessment, education, and treatment of women at risk for CVD.
Purpose of the EBP project
All women are at risk for CVD; therefore, preventive screening based on
demographic characteristics, comorbid conditions, lifestyle behavior, and risk factor
assessment should be routinely performed in the clinical setting in accordance with
national guidelines. The first step in disease prevention is recognizing risks which can
only be accomplished through performing screening assessments. Screening involves
the routine evaluation of asymptomatic people for detection of risk or disease. Available
clinical data suggest that CVD is largely preventable and incremental benefits exist from
identification and improved control of modifiable CVD risk factors. The purpose of this
EBP project was to screen asymptomatic women between the ages of 35-50 presenting
for their annual gynecologic exam for cardiovascular disease risk and stratification. This
approach affords a valuable tool for identifying a cohort of women who can benefit from
preventive treatments to modify or reverse CVD progression. Ultimately, efforts must
focus on expanding the number of women whose level of risk is accurately identified and
who are receiving evidence-based interventions for CVD risk reduction.
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The clinical question
The burning clinical question is: can asymptomatic women be accurately
identified for CVD risk factors and have their level of cardiovascular risk accurately
stratified? The advantage of implementing a standardized reliable risk assessment tool
is that it should be intuitively easy to initiate, takes into account the multifactorial nature
of CVD, assesses the appropriate variables, allows for a consistent measurement of risk
over time, and establishes a common language that can easily be understood among
practitioners.
PICOT
In women between the ages of 35-50 presenting for their annual gynecologic
exam, who are asymptomatic for cardiovascular disease, how does implementation of
the Framingham risk assessment model, compared to usual care (no screening), identify
the level of CVD risk over a three month period of time?
Significance of the project
In reality, 38.2 million U.S. women are living with some form of CVD while a
significantly higher percentage of women are at increased risk for developing CVD
(Carey & Gray, 2012). Beneficial reductions in major risk factors such as smoking, blood
pressure, and high cholesterol, account for more than half of the decreases in CVD
deaths (Perk et al., 2012). It is therefore imperative to implement CVD screening risk
assessment to identify and implement interventions to improve clinical outcomes and
reduce healthcare costs. Current guidelines emphasize assessing a woman’s CVD risk
factors throughout her lifetime. After the age of 50, women with even one risk factor will
have a substantially higher lifetime risk of developing CVD (Gleeson & Crabbe, 2009).
The ultimate goal of the EBP project is identifying asymptomatic women for their
cardiovascular disease risk within the OB/GYN practice setting. The OB/GYN practice
site has not traditionally assessed women for disease not related to the reproductive

SCREENING CARDIOVASCULAR RISK

12

system. The reasoning behind this has been multi-factorial and includes lack of
awareness, lack of understanding and comfort level of garnering metrics on CVD, feeling
that it is the responsibility of the PCP to screen, not being comfortable treating risk
factors for CVD, and not having a referral mechanism in place. In the implementation
site for the EBP project, some of these barriers were articulated; however assurance
was rendered to the clinical provider staff that the FNP would be responsible for patient
follow up and referral.
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CHAPTER 2
THEORETICAL FRAMEWORK AND REVIEW OF LITERATURE
In this chapter, the DNP project manager will discuss the two theoretical
frameworks that were used to guide the EBP project. The strengths and limitations of the
framework and its applicability to the project will be discussed. A review and appraisal of
the literature that supports the underpinnings of the project will be addressed in detail.
Theoretical framework
The theoretical frameworks chosen for this EBP project were Norla Pender’s
Health Promotion Model (HPM) and the Stetler model of EBP. These models were
chosen for their applicability to the EBP project. Each of the frameworks will be
discussed in detail in the following section.
Description of the theoretical framework
The HPM was developed by Norla Pender as a holistic predictive model of health
promoting behavior for application in the clinical practice setting. The model attempts to
explain and predict human behavior in regard to individual health choices and behavior.
The HPM has its theoretical roots in the expectancy value theory and the social cognitive
theory. The expectancy theory purports that individuals engage in actions to achieve
goals that are perceived to be possible and that have valued outcomes (Strof & VelsorFriederich, 2006). The social cognitive theory reveals the interconnectedness of
thoughts, behavior, and environment in their effect on behavior (Strof & VelsorFriederich, 2006). Pender articulates that health promotion, defined as behavior
motivated by the desire to increase well-being and actualize human health potential, and
disease prevention, defined as behavior motivated by the desire to avoid illness, should
be the primary impetus in health care (Pender, Murdaugh, & Parsons, 2011).
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The HPM has been validated in numerous clinical studies. With regard to the
benefit of action of the model, the test-retest reliability score is 0.86 and Cronbach’s
alpha is 0.75-0.88; in the barriers to action component of the model the test-retest
reliability is 0.75 and Cronbach’s alpha is 0.75-0.84 respectively (Pender, Murdaugh, &
Parsons, 2011).
One of the most challenging roles for the practicing clinician is to identify the
motivating factor that will provide the impetus for eliciting health behavior change in the
patient. The goal of primary prevention is to focus on being proactive with one’s health
versus being reactive when disease occurs. There are eight maxims of the HPM that
purport to characterize health behavior. The first maxim is the perceived benefit of the
action that must be realized by the patient: the individual must foresee the positive
consequences of undertaking a health behavior change. Secondly, the patient must be
able to identify the perceived barriers to action, the perception of blocks and personal
costs of undertaking a health behavior change. The third maxim is perceived selfefficacy and the judgment of personal capability to organize and execute a particular
health behavior and complete it successfully. The fourth maxim is the activity-related
affect involving the emotional component of health during and following a specific health
behavior. The fifth maxim revolves around the interpersonal influences of family, peers,
and healthcare providers. This may be the most tenuous construct to achieve as the
interactions and compelling forces of peers and family outside of the clinical practice are
typically more persuasive than the advice and recommendations of the healthcare
practitioner. The sixth maxim involves situational influences or the perception of the
compatibility of life context or environment with engaging in a specific health behavior.
The seventh maxim is the commitment to a plan of action with the intention to carry out a
particular health behavior including the identification of specific strategies to do so
successfully. Lastly, the patient must evaluate the immediate competing demands and
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preferences that deter changing health behaviors. It is commonplace in clinical practice
to hear a barrage of reasons for not completing or continuing a health behavior change.
As a clinician, these excuses must be discussed and a plan formulated to repudiate
these barriers so that the patient can actively pursue behavioral change.
Research has shown that an individual will take health-related action when there
is “a perceived threat to personal health and when the conviction that the benefits of
taking the action to protect health outweigh the barriers that will be encountered”
(Pender, Murdaugh, & Parsons, 2011, p. 38). One of the roles of the healthcare provider
is to discern what the perceived health threat would be to each individual patient and
capitalize on that belief to effect change in health behavior.
Application of the theoretical framework to the EBP project
Health promotion and disease prevention should be the primary emphasis within
the health care environment. It has been succinctly elucidated that the majority of
cardiovascular risk factors are modifiable. After critical assessment of numerous
theoretical foundations, it was determined that the Pender model is particularly
applicable to this EBP project. The HPM provides an excellent foundation for guiding the
identified cohort to become actively involved in health promotion and prevention
outcomes. Young and Capezuti (2010) postulated that the health promotion model
allows for examining factors associated with improved health promotion and allows
focusing on personal and environmental factors that influence health. It is imperative for
patients to change their modifiable risk factors in order to prevent or reduce the burden
of CVD. The eight maxims of the HPM clearly delineate behavior and cognitive
constructs that determine health promoting behaviors. The health promotion model has
been validated in research to be beneficial in promoting positive health behavior change
in people.

SCREENING CARDIOVASCULAR RISK

16

Strengths and limitations of the theoretical framework
The primary concern for health care providers is to promote health and prevent
disease for each individual patient. The principal strength of the HPM is the identification
of factors that influence health behavior. Evaluation of the eight maxims provides a
logical progression to improve heath and health behaviors. The definitions of the
concepts are clear and unencumbered, making them easily understood by health
professionals. Strof and Velsor-Friederich’s (2006) analysis of the HPM indicates that
self-efficacy and behavior specific cognitions are supported as a predictive variable in a
myriad of studies. Identification of benefits and barriers to positive health behavior plays
a role in predicting individual health behavior.
The HPM would ideally empower patients with unhealthy behaviors to make
necessary changes to promote and improve their health. The HPM can be a beneficial
tool for increasing patient awareness and perception of CVD risk factors and facilitating
positive behavioral health change. Bennett, Perry, and Lawrence (2009) believed that
health behaviors must be in the control of the patient and possess meaning for the
patient in order to be effective. Using the HPM as a framework while interacting
collaboratively with the patient, the clinician can identify the barriers that impede patients
from achieving optimal health.
One of the limitations to the HPM is that the relationship between the constructs
is not clearly identified. Although interrelated, there is not a clear linear relationship
between the various constructs. Some constructs are more powerful than others in
affecting health care behavior. Peterson & Bredow (2009) articulated: “Although the
model identifies foci for nursing interventions, it does not explicitly describe how nurses
can effect changes in client perceptions” (p. 296). Practitioners in a busy clinical setting
may find evaluation of eight constructs to be cumbersome and untenable as well as time
prohibitive.
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There are specific assumptions associated with the HPM including the
assumption that patients are able to self-reflect, actively seek to regulate behavior, and
initiate behaviors that modify their environment (Pender, 1996). This may not be the
case with each individual patient.
Time constraints of a routine clinical visit would preclude identification of all
tenets of the theoretical model and their level of significance for each individual patient.
Assisting patients to address the perceived barriers such a lack of discipline,
interference by family and peers, and application of change in daily behavior would be a
daunting time intensive task. The interaction of patient and provider regarding health
changing behavior and risk modification must be persistent and undeviating to effectively
elicit health behavior change. Although Pender removed threat of disease from her
original model, Peterson and Bredow (2009) pointed out that this may not always be
distinguished in practice; threat of disease may therefore continue to be a motivational
factor in promoting changes in health behavior. An additional barrier to implementation
of the HPM may be that the clinician doubts the patients’ willingness to change negative
behaviors and thus finds health promotion and disease prevention discussions to be a
waste of valuable time.
In summary, the HPM does provide a sound theoretical framework for promoting
change in health behavior. The HPM identifies individual behavior and factors that
restrict positive health promoting behavior. The premise of the model is to concentrate
on the barriers that impede individuals from achieving optimal health and preventing
disease. This model is persuasive for promoting CVD risk reduction in asymptomatic
women by identifying barriers, strengthening potential and capability, and putting the
responsibility for one’s health in their own hands making the patient a positive change
agent.

SCREENING CARDIOVASCULAR RISK

18

Description of the EBP model
The principles of EBP have become the cornerstone strategy for health care
providers to translate research into clinical practice (Facchiano & Hoffman-Snyder,
2012). Evidence-based practice is a problem solving approach to clinical care that
incorporates the conscientious use of current best evidence from well-designed studies,
a clinician’s expertise, and patient values and preferences (Fineout-Overholt, Melnyk, &
Schultz, 2005). The ever-changing health care environment compels practitioners to
synthesize the highest level of evidence into the decision making process. Although
there are a number of definitions used interchangeably for evidence-based medicine and
evidence-based practice, one of the most widely accepted definitions is by Sackett,
Rosenberg, Gray, Haynes, and Richardson (1996) who defined evidence-based
medicine “as the conscientious, judicious, and explicit use of current best evidence in
making decisions about the care of the individual patients” (p.71). The intent of EBP is
not to conduct new research but rather to synthesize clinical evidence from high levels of
previously published research and apply it to the clinical setting and to the individual
patient. Facchiano and Hoffman-Snyder (2012) concluded that “EBP is a strategy to
keep knowledge up to date, enhance clinical judgment, and lead to cost-effective
treatment modalities” (p.581). The Institute of Medicine (IOM, 2001) confirmed that it is
germane to base clinical decision making on scientific acumen that is evidence-based.
When EBP processes are integrated into our clinical practice settings they augment the
existing provider-client relationship and shared decision making process (Facchiano &
Hoffman- Snyder, 2012). The IOM (2001) has set forth a recommendation that 90% of all
clinical decisions be evidence-based by the year 2020. The EBP model chosen for this
project is the Stetler model of evidence based practice.
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Application of the model to the EBP project
Cheryl Stetler’s model of research utilization was one of the original models
developed for EBP. She originally developed the model in 1994 and then revised it in
2001. The purpose of the model is to formulate a series of critical thinking and decision
making steps that are designed to facilitate effective use of research findings (White &
Dudley-Brown, 2012). The Stetler model de-emphasizes practice based on tradition and
instead focuses on the use of research findings along with other credible sources of
data. The model focuses on both internal data (such as quality improvement,
operational, evaluation, and practitioner experience) and external data (such as primary
research and consensus of national experts) making the model comprehensive in nature
(Ciliska, et al., 2011).
The Stetler model is a series of five progressive critical thinking and decision
making steps designed to facilitate use of research findings in the clinical setting.
Preparation, validation, comparative evaluation/decision making, translation/application,
and evaluation represent the five building blocks of the model (Ciliska, et al., 2011).
The preparation phase initiates the EBP process by defining the clinical issue,
identifying the purpose, and affirming the priority of the identified clinical question. During
the initial phase consideration is given to both internal and external factors which may
create barriers to implementation. Potential barriers may include organizational
expectations/norms, peer expectations, resource availability, and timelines. The PICOT
question is formulated to clarify and organize the patient population, intervention of
interest, comparison of interest, outcome of interest, and timeframe of the project (Romp
& Kiehl, 2009). It is during the preparation phase that the researcher identifies
measurable outcome goals and expectations for the project.
The clinical issue identified by this DNP project manager relates to the lack of or
inconsistency of CVD risk screening in the female clients seen at Lifestages Center’s for
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Women. To reiterate the significance of this clinical issue, CVD being the leading cause
of death in women, is predominantly precipitated by modifiable risk factors. The clinical
conundrum is that unless CVD risk screening is implemented in the clinical setting and
risk identified, there cannot be evidence based interventions initiated. It is therefore
prudent to implement a primary prevention modality to identify cardiovascular risk in
asymptomatic women. This DNP project manager, being an FNP, practices primary care
within an OB/GYN office setting. Many women identify their gynecologist as their primary
care provider, especially women of childbearing age. The usual CVD risk screening may
be opportunistic at best in this clinical setting. Not screening asymptomatic women for
cardiovascular risk in the clinical setting is negligently ignoring a disease that can easily
be modified to change the trajectory of cardiovascular disease progression. This DNP
project manager has been afforded a pristine opportunity to amass data on CVD risk
factors and stratification of risk in asymptomatic women presenting for their annual
preventive exam. This EBP project is a primary prevention intervention initiative.
Phase two of the Stetler model is the validation phase in which relevant literature
is critically appraised and synthesized for its applicability to the PICOT question. The
methodological review discerns adequate evidence to support the PICOT question. The
evidence is analyzed for its statistical and clinical significance as it relates to the clinical
question. The chosen evidence is rated for its level and quality and catalogued in an
evidence table for easily accessible visualization. It is during this phase that reflection of
the studied variables and their relationships are assessed in terms of their applicability to
the clinical practice issue. Although a number of tools would provide CVD risk
stratification, the tool must be easily applied to the identified cohort and the practice
setting. The review of literature will be succinctly detailed in a following section.
Comparative evaluation/decision making is the third phase of the Stetler model.
Rigorous comparison of the cumulated evidence for similarities and differences is
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completed and the most applicable evidence for the project is garnered. Many sources
of evidence may be pertinent to the EBP but a myriad of parameters must be taken into
consideration such as feasibility, cost, time constraints, current practice fit, and
organizational buy-in before a final decision is made. Admittedly there are a
multitudinous number of risk prediction models articulated in the literature however, this
DNP project manager chose the Framingham risk prediction model for its reliability,
validity, national clinical guideline recommendations, and ease of use in the clinical
practice setting.
Phase four of the Stetler model is the translation/application phase. Using the
summary statements from phase three, the DNP project manager articulated
implementation methodology of the synthesized findings specific to the EBP project. This
phase specifically delineates the type of research, method of use, level of use, any
variation of use, and the plan for dissemination and change strategies (Stetler, 2001).
A convenience sample of women between the ages of 35-50 who presented to
Lifestages Samaritan North office for their annual gynecology exam, and who were
asymptomatic for CVD, were offered CVD risk assessment. Women were assessed by
the nursing staff for inclusion/exclusion criteria, the nursing staff obtained informed
consent, inputted demographic and measurement values onto the questionnaire, and the
medical practitioner seeing the patient ordered a fasting lipid and metabolic panel if not
previously done within the past 12 months. The questionnaire along with the laboratory
metrics were forwarded to the DNP project manager for input into the web-based risk
prediction tool database.
Implementation of a practice change can be challenging therefore, a myriad of
methods of dissemination of information to key stakeholders must be considered.
Communication was done via provider meetings, staff meetings, individual meetings, email reminders, personal interaction with providers and staff, use of power point
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presentations, as well as active involvement by the marketing director and practice
manager. Data collection and coalescing of data took place over a 12 week time period.
Tacit valuing, enthusiasm, and awareness of the EBP project are consequential
for its success in the clinical practice setting. Anticipation of potential barriers and
methods to circumvent these barriers must be in place prior to the implementation
phase. This DNP project manager was available at all times, either physically present in
the practice setting or via telecommunication, should obstacles be encountered.
Phase five of the Stetler model is the outcome/evaluation phase. Evaluation of
the EBP project was based on expected outcomes relative to the PICOT question.
Differentiation of formal and informal evaluation as it relates to applying the findings to
clinical practice was rendered. Statistical analysis using the SPSS 20 statistical software
was completed on the garnered data for its significance and credibility to the clinical
question. Assimilation of the findings was disseminated to the provider and nursing staff
through group staff meetings and power point presentations. The final phase of the
Stetler model is continuous and ongoing as the practice change is made a permanent
change in clinical practice.
The Stetler model is a practitioner-oriented model with a focus on critical thinking
and the application of research findings applied by an individual practitioner. The model
maintains the core assumptions that research based recommendations are applied at
the skilled practitioner level to individual patients or other identified groups (Melnyk &
Fineout-Overholt, 2011). Albeit the Stetler model is an individual practitioner oriented
model rather than an organizational focused model, it is desirable to have a supportive
organizational culture. The organizational culture must propagate leadership support for
evidence-based practice foci, have the capacity to engage in EBP, have an effective
implementation framework, and have an infrastructure to maintain an EBP milieu. The
choice of this model was in part due to a collective acknowledgement within the provider
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group identifying the exigency to screen women for cardiovascular disease risk. The
leadership culture supports the EBP project and deems it crucial in meeting primary
prevention goals and in providing comprehensive healthcare screening to women.
Implementation of the EBP was an individual practitioner endeavor with expected
outcome and data analysis to support the commitment to continue cardiovascular risk
screening as an organization wide endeavor.
Strengths and limitations of the EBP model in the context of the EBP project
The Stetler model of EBP provides a conceptual framework to elicit a clinical
practice change. The models assumptions and action steps are grounded in research
and are interactive in nature. The model emphasizes critical thinking and is intended for
the practicing clinician. The model affirms the expertise and experience of the clinician to
apply evidence-based guidelines in the clinical practice setting. The logical progression
of the various phases of the model provided substantiating evidence to support a
needed change in current clinical practice. Critical appraisal of the evidence helped
ascertain the best fit for answering the clinical question and aided in identifying the
evidence that was most apropos for use in the OB/GYN clinical setting.
A potential limitation to the model is the paucity of change theory discussion
within the implementation phase of the model. Change causes angst both individually
and collectively within the work environment. Staff may perceive the screening
implementation to be more work for them, staff may feel that the traditional way of doing
things is fine, and concern arises as to what will be done with the data garnered from
implementing a risk assessment screening. Providers have voiced concern regarding
their level of comfort in primary prevention screening and their responsibility in
relationship to intervention and referrals based on risk prediction scores. These
concerns were encompassed as part of the education prior to implementation and were
ongoing throughout the EBP project.
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The decisions rendered during a clinical practice change and used within the
context of practice must be replicable, observable, credible, verifiable, and supportable
(Melnyk & Fineout-Overholt, 2011). EBP is a strategy to keep knowledge up to date,
enhance clinical judgment, and lead to cost-effective treatment modalities (Facchiano &
Hoffman-Snyder, 2012). Adopting EBP in the clinical setting enables the clinician to
present EBP recommendations to patients and involve them in the clinical decision
making process.
Literature search
Using key words from the PICOT question, a cogent number of health care data
bases were searched for current relevant evidence related to cardiovascular risk
assessment in asymptomatic adults. In alignment with the evidence-based process,
rigorous research must be appraised and be included in the clinical practice setting to
improve the quality of healthcare and patient outcomes (Melnyk & Fineout-Overholt,
2011). This DNP project manager searched a salient number of word combinations and
phrases to compile a body of evidence that best related to the EBP project and the
PICOT question. This rigorous search for evidence was labor intensive and difficult to
amalgamate into tangible units of useable information. There was a dearth of evidence
on CVD risk factors and cardiovascular prediction models to appraise and classify.
Sources examined for relevant evidence
The search engines used for ascertaining highly relevant current evidence
included: CINAHL, Joanna Briggs Institute (JBI), Cochrane databases, PubMed, Google
Scholar, National Guideline Clearinghouse, and MEDLINE via EBSCO. A combination of
search terms used in each search engine included: cardiovascular disease, women,
cardiovascular risk assessment, screen, tools, interventions, cardiovascular risk factors,
and Framingham heart study.
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Inclusion criteria consisted of peer reviewed scholarly journals, evidence-based
or research articles, English language, and date range of 2008-2013. Exclusion criteria
were articles written in a foreign language, research older than 2008, evidence that was
not pertinent to the evidence-based project, and sources that were not high levels of
evidence.
In the CINAHL database, an initial search using the identified terms yielded a
total of 31 articles that matched the search criteria. Of these identified articles, five were
pertinent to the evidence-based project. Of these research articles, two were included in
the appraisal of evidence due to their applicability to cardiovascular risk factor
identification and the pertinence of the Framingham risk score in screening
asymptomatic adults. Joanna Briggs Institute (JBI) returned 38 articles matching the
search terms that were entered. Analytical analysis of the evidence yielded one
evidence summary relevant to the EBP project. This evidence summary demonstrated a
high level of quality evidence. Many of the evidence summaries were more applicable to
interventions of identified cardiovascular risk factors rather than the role of risk factors in
the development of cardiovascular disease. Albeit valuable evidence, this EBP project
focus was on identifying cardiovascular risk factors rather than focusing on interventions
to change the trajectory of the significance of the risk factor as it relates to CVD
development. A search of the Cochrane database returned a total of 82 potentially useful
articles of high level evidence. A multitudinous number of these were focused on
interventions rather than on risk assessment screening. After critical review of the
abstracts and sifting through the research, three high quality evidence articles were
included in the appraisal of relevant literature. PubMed resulted in a consequential
number of applicable evidence. Using the identified search terms, 139 results were
returned. Assessing the evidence culminated in five usable articles. Systematic reviews
of risk prediction model comparisons along with systematic review of cardiovascular risk
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factors were gleaned and found applicable to the EBP project. Google Scholar yielded a
plethora of hits and was very onerous to narrow the search to relevant evidence for the
EBP project. This search engine was a source of frustration as attempts at narrowing
search terms still apportioned an abundance of potential research, but many did not
match the defined criteria for the EBP project. After reviewing the returned abstracts,
three articles were found to meet inclusion criteria and deemed appropriate for the EBP
project. The National Guideline Clearinghouse search criteria resulted in 87 potentially
appropriate articles. Analyzing the guidelines and articles resulted in four germane
guidelines and articles appropriate for the EBP project. MEDLINE search terms accrued
an initial 4104 results that matched the search parameters. Further narrowing of criteria
resulted in a total of 47 articles that were reviewed and evaluated which terminated in
two articles for integration into the appraised evidence. Once the evidence was
amalgamated, hand searching was completed for any supplementary pertinent research.
Levels of evidence
The evidence was evaluated and categorized based on the hierarchy of evidence
pyramid delineated by Melnyk and Fineout-Overholt (2011). These levels of evidence
range from I, the highest level of evidence to VII, the lowest level of evidence. These
levels of evidence are connoted in the note to Table 1.1 which provides summaries
inclusive of author(s), date and type of study, study design, outcomes and relevance to
the EBP project and clinical practice.
The levels of evidence from the 20 included research articles ranged from Level I
to Level VI. Included in the appraised evidence were 14 Level I systematic reviews or
clinical guidelines, four Level IV which included two case control studies and two cohort
studies, and two Level VI studies, one which was a single descriptive study and one that
was a cross sectional study. Clinical practice guidelines were appraised using the
Appraisal of Guidelines for Research & Evaluation (AGREE II) and all other research
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was appraised using the Critical Appraisal Skills Programme (CASP). The appraisal of
current relevant research yielded a significant number of high levels of evidence.
Appraisal of relevant evidence
A total of 20 articles were included in the appraisal of evidence and are
summarized in Table 1.1. An examination of this evidence will be discussed in greater
detail in the following section.
Table 1.1 Levels of Evidence
Author(s)

Level of evidence Study design

Outcomes

Implications___

Siontis et al. 2012
Comparisons of
established risk
prediction models
for cardiovascular
disease: systematic
review

Level I Systematic
Review

Comparative
predictive model
studies included 56
pairwise comparisons
of 8 cardiovascular
prediction models.
Medline and citation
search of studies
compared at least 2
major risk models in
the general
population.

One model was no
better than another
in cardiovascular
disease risk
stratification.
Limitations included
same geographic
areas, same study
population
(European), no
language restriction,
sample size or
duration limits.

Clinical usefulness of
the various models is
based on their
potential for
affecting decisions
on treatment and
prevention and
improving health
outcomes. The FRS
model was
compared in 50/56
pairwise
comparisons, the
reliability and validity
of the model had
previously been
validated.

Matheny et al., 2011
Systematic review of
cardiovascular risk
assessment tools

Level I Systematic
Review

Comparison of
externally and
internally validated
risk prediction
models that included
prospective and
randomized
controlled trials.
Study designs were
accepted if
evaluation was of
asymptomatic
patients. Medline
search from 19992009 and reference
searching was done.

The objective the
USPSTF sought to
determine was if a
specific model
performed better
and therefore would
be more applicable in
a primary care
setting. The FRS
models performed
well in the U.S.
population, the
newer models being
more predictive than
older models.

Evidence supports
use of the FRS in a
primary care setting.
It has been
compared to global
models and has
performed
successfully in the
U.S. population. This
tool will be
applicable for this
DNP project
manager to apply to
the EBP project study
population.

Hsu, et al., 2013
A clinician’s guide to
the ABC’s of
cardiovascular
disease prevention:

Level IV Case
Control

INTERHEART case
control study
comparing the FRS
model and RRS
model

Comparison of the
FRS and the RRS
model in 9
modifiable risk
factors. The RRS

The RRS assessment
adds family history
and CRP-hs to the
FRS which
demonstrated more
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model includes
family history and
CRP-hs. When
applied to 25,000
asymptomatic
women identified as
low risk by the FRS,
40% were reclassified
at a higher risk when
the RRS was applied.

women were
stratified to a higher
risk level. CRP-hs is a
costly laboratory test
that may not be
applicable to use in
the OB/GYN practice
setting. One of the
goals of risk
assessment
screening is to make
it readily available
and easy to apply to
the identified cohort.

Cooney et al., 2010
Cardiovascular risk
estimation systems
in primary
prevention: Do they
differ? Do they
make a difference?
Can we see the
future?

Level I Systematic
Review

RCT’s comparing risk
models focusing on
rationale for
estimating
cardiovascular risk,
comparison of
current models for
reliability and
validity, and whether
evidence exists that
cardiovascular risk
estimation improves
patient outcomes.

The rationale for
implementation of
risk modeling is that
CVD is the result of
combined effect of
several risk factors.
Patients identified
with high risk who
are randomized to
interventions have
shown greater
reduction in risk
factor levels and
decreased
cardiovascular
disease.

The FRS model was
identified as the best
known nationally
and internationally
and the most
commonly used risk
prediction model. To
be used clinically, the
risk model must be
methodical, robust,
easy to use, and be
able to detect
clinically relevant risk
factors. The FRS
model meets these
criteria and will be
applicable in the EBP
project site.

Mosca et al., 2011
Effectiveness-based
guidelines for the
prevention of
cardiovascular
disease in women2011 update: A
guideline from the
American Heart
Association

Level I Systematic
Review

Review of RCT’s and
prospective cohort
studies that included
greater than 1000
women. This was a
follow-up to the 2007
guideline. PubMed,
Embase, and
Cochrane were
searched using the
date ranges of 20062010.

There were
significant changes
from the 2007
guidelines.
Effectiveness of
prevention therapies
was added to the
previous guidelines.
It was demonstrated
that preventiom
strategies were
shown to have
sufficient evidence
and clinical benefit in
regard to CVD
outcomes. An
algorithm was
established for the
evaluation of CVD
risk.

This systematic
review was
particularly
applicable to the EBP
implementation site
as it succinctly
discussed barriers to
screening in this
clinical setting. The
authors also
delineated
disparities in CVD
screening and
interventions. The
authors discussed
the imperativeness
of screening younger
women (ages 35-54)
which is similar to
the inclusion criteria
age range for this
DNP EBP project.
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Perk et al., 2012
European guidelines
on cardiovascular
disease prevention
in clinical practice

Level I Clinical
Practice Guidelines

The Joint Taskforce
of the European
Society of Cardiology
along with eight
other societies who
focus on CVD
prevention reviewed
current levels of
evidence and
recommendation
from RCT’s and
systematic reviews to
create current
practice guidelines.
Evidence was
analyzed on the
GRADE criteria to
establish quality of
evidence and
strength of
recommendation.

In apparently healthy
persons, CVD risk is
most frequently the
result of multiple
interacting factors.
Good clinical
guidelines are a
major mechanism to
improving the
delivery of
healthcare and
improving patient
outcomes. 50% of
reductions seen in
CVD mortality are
related to changes in
risk factors.

The evidence
supports the need
for assessment of
CVD risk factors in
the clinical practice
setting. Assessment
of risk and
intervention is
significant in
reducing CVD
mortality and
improving health
outcomes in the
general population.
The European
consensus supports
the necessity of
screening
asymptomatic
patients.

Colagluri et al., 2009
Guidelines for the
assessment of
absolute
cardiovascular risk

Level I National
Guideline
Clearinghouse

Data base search of
Australasian Medical
Index, CINAHL,
Cochrane database,
EMBASE, EBM
(OVID), and Medline
including systematic
reviews and RCT’s
that compared the
predictive ability of
different methods of
risk assessment. A
total of 20,991
studies were
narrowed down to 30
studies that met
inclusion criteria.
Among the clinical
questions to be
answered in the
guideline was to
determine which risk
assessment method
is most predictive of
future CVD events in
a mixed adult
population without a
diagnosis of CVD.

Modeling studies
were appraised and
it was found that the
most cost-effective
strategies for
preventing CVD are
those that direct
intervention
strategies on CVD
risk assessment
rather than targeting
on individual risk
factors in isolation.
The highest level
recommendation in
the guideline is that
absolute CVD risk
assessment, using
the FRS equation to
predict risk of a
cardiovascular event
of the next 5 years
should be performed
on all adults between
the ages of 45-74
who are known to
not have CVD.

Modeling studies
provide compelling
current evidence
that CVD risk
assessment in
general practice is
likely to improve
CVD outcomes and
direct
patient/clinician
decision-making on
risk reduction
strategies. These
guidelines
recommend the FRS
tool as the initial
assessment tool to
ascertain CVD risk in
asymptomatic
patients. The FRS
assessment tool is
the identified tool
for use in this DNP
EBP project. The FRS
model was chosen
for its reliability and
validity and its ease
of use in the clinical
practice
environment.

Dykova, M., Drew,
C., Wright, N.,
Clarke, A., & Rees, K.
2013 Systematic
versus opportunistic

Level I Review of
RCT’s

The primary
objective of this
review was to assess
the effectiveness,
costs, and adverse

A standard
assessment based on
simple questions and
measurements
would be effective in

This Cochrane review
is most applicable to
this DNP EBP project
as the methodology
for implementation

SCREENING CARDIOVASCULAR RISK
risk assessment for
the primary
prevention of
cardiovascular
disease. The
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Greenland et al.,
2010
ACCF/AHA guideline
for assessment of
cardiovascular risk in
asymptomatic adults

Level I Clinical
Practice Guidelines
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effects of systematic
risk assessment
compared to
opportunistic risk
assessment for the
primary prevention
of CVD. RCT’s
included individuals
without diagnosis of
CVD. The two types
of interventions
appraised included
systematic risk
assessment for
primary prevention
of CVD, defined as
screening involving a
pre-determined
selection process
where asymptomatic
individuals
systematically
received risk
assessment and
opportunistic risk
assessment
screening which
occurs sporadically
and without
identified guidelines.

identifying CVD risk
in asymptomatic
individuals.
Systematic risk
assessment was
deemed to be more
effective in
identifying levels of
risk and was more
cost effective than
opportunistic
assessment.

will be a systematic
approach versus an
opportunistic
method.
Opportunistic
assessment would
miss a large
percentage of
individuals who are
not being screened
for CVD risk. This
practice setting
currently has no
standardized tool or
method to screen
women for CVD risk.
Opportunistic
assessment would be
disorganized,
disjointed, and
would not address
the health needs of
the identified
population nor
accurately assess for
CVD risk.

Rigorous search of
the evidence was
done and guideline
recommendations
were prioritized
based on the type of
studies that were
done. Level A
recommendations
were based on data
derived from
multiple RCT’s or
meta-analyses. Level
B data was derived
from single RCT or
nonrandomized
studies. Evidence was
ranked as C when the
primary source was
consensus opinion,
case studies, or
standard of care.
These guidelines are
specific to
populations residing
in North America.

The guidelines are
intended to assist
health care providers
in clinical decision
making. The
guidelines attempt to
define practices that
meet the needs of
most patients in
most situations
making them
generalizable to a
myriad of practice
settings. The goal of
early assessment of
CVD risk is to provide
a foundation for
targeted preventive
efforts based on that
individual’s predicted
risk. The guideline
proves an evidencebased approach to
risk assessment. The
first
recommendation is
for the use of global

Guidelines that are
generalizable in a
myriad of practice
settings provide data
that has enhanced
reliability and
validity. These
practice guidelines
are entrenched with
high levels of
evidence. These
guidelines are
applicable to this
DNP EBP project as
they focus on an
initial assessment of
risk in asymptomatic
or apparently
healthy adults.
Another applicable
delineation of the
guideline is that
there is no specific
identified age when
risk assessment
should be
completed. The
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risk scores, such as
the FRS that
evaluates multiple
cardiovascular risk
factors to assess all
asymptomatic adults
without clinical
history of
cardiovascular
disease.

recommendation
states that risk
identification can be
done at any age even
beginning in children
or adolescents. This
is pertinent as some
guidelines
recommend
screening women
beginning at age 50
which may be too
late to initiate
primary prevention
practices. The
identified age range
for this EBP project is
35-50.

Worrall-Carter, L.,
Ski, C., Scruth, E.,
Campbell, M., &
Page, K. 2011
Systematic review of
cardiovascular
disease in women:
Assessing the risk

Level I Systematic
Review

A search of the
published literature
was done for the
time period of
January 1999-June
2011. PubMed,
CINAHL, Embase,
PsychINFO, and
Medline were among
the search engines.
58 papers were
critically appraised.
Inclusion criteria
were studies using
meta-analyses,
systematic reviews,
and literature
reviews.

The FRS assessment
was identified as a
consistent tool that
contributes to
understanding CVD
risk factors.
Modifiable risk
factors such as
hypertension,
dyslipidemia,
inactivity, BMI,
smoking, and
nutrition continue to
be consistently
identified in the
literature. Focus
must be on
identification of
these risk factors so
that interventions
can be initiated,
hopefully changing
the course of CVD
progression.

In research
endeavors women
have traditionally
been excluded or
under represented.
Many CVD risk
prediction factors
are modifiable; the
key is effective and
relevant risk factor
identification. The
FRS model has been
assessed for validity
and reliability and
has historically
performed well in
the U.S. population.
This tool will be the
assessment tool in
the EBP project.

Read, S. 2010
Cardiovascular
disease: Risk
estimation and
prevention. The
Joanna Briggs
Institute

Level I Systematic
Review

This evidence
summary is based on
a structured search
of the literature
using evidence-based
health care data
bases. Studies
included for appraisal
consisted of RCT’s,
prospective cohort
studies, and one
nested case-control
study.

The clinical question
was: what are the
significant risk
factors related to the
prevention or
reduction of risk of
CVD among adult
populations? Best
practice
recommendations
for modifiable risk
factors were graded
and supported by
current evidence.

This systematic
review continues to
validate the
necessity for
screening
asymptomatic
individuals for
modifiable CVD risk
factors. Risk factors
should be identified
and stratified for
comprehensive
assessment of risk.
The FRS model does
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The modifiable risk
factors articulated
included smoking,
hypertension,
dyslipidemia,
inactivity, alcohol
consumption, dietary
fats, and
recommendations on
fruit/vegetable
intake.

not specifically
assess dietary intake
or physical activity
but can be
correlated with BMI,
waist circumference,
and laboratory
testing.

Murphy, T.,
Dhangana, R.,
Pencina, M., Zafar,
A., & D’Agostino, R.
2011
Performance of
current guidelines
for coronary heart
disease prevention:
Optimal use of the
Framingham- based
risk assessment

Level IV Cohort
Design

This study was a
retrospective analysis
of two prospective
cohort studies. The
Atherosclerosis Risk
in Communities and
the Cardiovascular
Health Study
included 11,436 and
2569 participants
respectively. These
individuals were
without CVD or
diabetes at baseline.
The FRS variables
were analyzed.
Receiver Operating
Characteristics (ROC)
curves, sensitivity,
specificity, accuracy,
and other test
performance
characteristics were
determined at
various 10 year risk
thresholds.

The FRS was
significantly
associated with
coronary heart
disease. 10 year
incidence rates for
hard coronary heart
disease such as MI or
stroke strongly
correlates with FRS
categories. The
incidence rates were
higher in the
Cardiovascular
Health Study most
likely due to an older
population. The
authors observed
that the limitations in
risk prediction were
not in the correlation
of the risk prediction
algorithm with
subsequent events,
which demonstrated
good correlation
across risk
categories, but in the
threshold that is used
to dichotomously
determine high risk.

Current guidelines
recommend
Framingham risk
scoring to be used to
categorize risk and to
plan evidence-based
interventions.
Identification and
intervention can
reduce negative
outcomes and
reduce health care
costs. The
Cardiovascular
Health Study was
conducted in an
older population
which makes it less
generalizable to the
cohort in the EBP
project. The
Atherosclerosis Risk
in Communities
included white and
African American
men and women
between the ages of
45-64 which is more
applicable to the age
range of the EBP
project.

McGorrian et al.,
2011
Estimating
modifiable coronary
heart disease risk in
multiple regions of
the world: The
INTERHEART
modifiable risk score

Level IV Case
Control Study

Multiple logistic
regressions were
used to create the
INTERHEART
modifiable risk score
(IHMRS). Internal and
external validation
was completed.
N=19470 were
evaluated from the
case control study
assessing nine
modifiable risk
factors with MI being

Results were
consistent across
ethnic groups and
geographic locales.
Nine modifiable risk
factors were
predictive in
determining risk for
MI. These risk factors
included
apolipoprotein levels,
smoking, blood
pressure, diabetes,
abdominal obesity,

Risk stratification is
suggested as best
practice for the
management of
individual CVD risk.
Risk assessment
tools have
demonstrated
accuracy in
determining risk.
This tool would be
more cumbersome
in the clinical
practice setting as
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Tattersall, M.,
Gangnon, R.,
Karmali, K., & Keevil,
J. 2012
Women up, men
down: The clinical
impact of replacing
the Framingham risk
score with the
Reynolds risk score
in the United States
population

Level VI Evidence
from a single
descriptive or
qualitative study
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the end point.
Participants were
from 52 different
countries.

psychological factors,
dietary factors,
physical exercise, and
alcohol consumption.
The INTERHEART
case control study
demonstrated that
these nine modifiable
risk factors account
for 90% of the
population
attributable risk for
MI.

some of the risk
factors are subjective
in nature versus
objective and it
would be time
prohibitive to
ascertain some of
the subjective
variables. Degree of
second hand smoke
exposure, definitions
of stress, depression
and anxiety would be
difficult to measure.
Use of the
Framingham risk tool
provides objective
data that is
standardized and
would lend itself to
statistical analysis. A
multivariate risk
prediction tool
gleans data that
identifies and
stratifies levels of
CVD risk.

Using the National
Health and Nutrition
Examination Surveys
(NHANES) the FRS
and the Reynolds risk
score (RRS) was
applied to 2,502
individuals who were
free from CVD. The
RRS has additional
risk assessment
variables in addition
to the variables
assessed by the FRS.
The RRS includes
hemoglobin A1C and
CRP-hs which are not
included in the FRS.

Compared to the
FRS, the RRS assigns
a higher risk category
to 13.9% of the
women and a lower
risk score to 2% of
the women that
were evaluated in
the study. In the U.S.
population, the RRS
assigns a new risk
category in one of
every six women.

Clinician use of CVD
risk stratification
results in evidencebased interventions
and potential
reduction in CVD
burden. Risk models
differ in variables,
definition of end
points, and the
population in which
they were developed
and validated.
Guidelines for best
practice recommend
routine screening for
CVD risk in
asymptomatic
individuals. This DNP
project will
implement the FRS in
asymptomatic
women in an
OB/GYN setting. Ease
of use of a validated
tool is going to be
most imperative in
initial screening for
this cohort and this
practice setting.
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Although the RRS
reclassifies many
women into a higher
risk category, the FRS
is a validated reliable
tool to use as a
primary prevention
intervention. Cost
consideration must
be considered when
expecting patients to
complete laboratory
testing as CRP-hs and
Hgb A1C are not
considered initial
screening labs.

Katsiki, N.,
Papadopoulou, S.K.,
Fachantidou, A.I., &
Mikhailidis, D.P.
2013
Smoking and
vascular risk: Are all
forms of smoking
harmful to all types
of vascular disease?

Level I Systematic
Review

Medline was
searched for relevant
publications using
keywords related to
smoking and CVD,
risk, primary and
secondary
prevention. The most
recent evidence was
reported. All forms of
smoking including
cannabis, cigar, pipe,
smokeless tobacco,
and cigarette
smoking were
evaluated in the
study.

Although all forms of
smoking were
associated with an
increased risk for
CVD, cigarette
smoking garnered
the highest risk and is
the variable assessed
by the FRS model.
Acute active as well
as passive smoking
increases CVD
morbidity and
mortality. A
Cochrane systematic
review found that
smoking cessation
was associated with a
significant reduction
in the risk of allcause mortality
related to CVD.
Smoking also
interacts with several
vascular risk factors
such as hypertension,
diabetes,
dyslipidemia, and
homeostasis which
further amplify CV
risk.

Smoking is a
significant
modifiable risk factor
for the development
of CVD. In addition
to smoking being an
independent risk
factor, it acts
synergistically to
amplify risk when
combined with other
risk factors. The FRS
does assess for
smoking status. The
U.S. surgeon general
has articulated
smoking as being the
single greatest cause
of avoidable
morbidity and
mortality in the U.S.
Smoking is dose
related but cessation
of smoking allows
rapid approach to
CVD risk of never
smokers. As
clinicians, it is
imperative to
evaluate for smoking
history and to
incorporate
interventions for
smoking cessation in
the practice setting.

Al-Ansary et al.,
2013
A systematic review
of recent clinical
practice guidelines

Level I Systematic
Review

Medline, EMBASE,
guideline websites,
and Google were
searched for clinical
practice guidelines

A large systematic
review of 147 trial
reports on the
management of
hypertension has

All CPG’s
recommend
assessing for
hypertension in
relation to other CVD
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on the diagnosis,
assessment, and
management of
hypertension

Mohebi, R.,
Bozorgmanesh, M.,
Azizi, F., & Hadaegh,
F. 2013
Effects of obesity on
the impact of shortterm changes in
anthropometric
measurements on
coronary heart
disease in women

Level IV Prospective
Cohort Study

35

(CPG) written in
English between
2006-2011. The
search strategy
yielded 2168
citations of which
114 were considered
and 11 were
included. The CPG’s
were evaluated using
the AGREE-II
instrument.

shown that a mere
reduction in 10 mm
Hg in systolic blood
pressure and 5 mm
Hg in diastolic blood
pressure was
associated with a
20% reduction in
coronary heart
disease and a 32%
reduction in stroke in
one year. The
continuous and linear
relationship between
systolic blood
pressure and
coronary risk is true
for both men and
women.

risk factors during
patient assessment.
Blood pressure
measurement is one
of the variables
assessed with the
FRS. Measurement
of blood pressure is
clinically relevant as
population
attributable risk
methods suggest
approximately 54%
of all strokes and
47% of all ischemic
heart disease is
attributable to high
blood pressure,
resulting in 7.6
million annual
premature deaths
worldwide. Modest
reductions in blood
pressure
measurements
results in significant
reductions in CVD
risk.

This prospective
design consisted of a
sample of 2468
women over the age
of 30 without a
diagnosis of CVD.
This was sample was
followed for a period
of 6.6 years (mean).
Cox proportional
hazard regression
was performed to
estimate the hazard
ratios of
anthropometric
measures for
cardiovascular
events.

During the follow up
period, 5.1% of the
participants
exhibited a CV event.
There was a
significant interaction
between BMI and
anthropometric
changes in prediction
of CV events (p< .04).

Obesity, defined as a
BMI ≥ 30 kg/m² is a
conventional risk
factor for CVD. 68%
of Americans are
now considered to
be overweight or
obese. According to
these authors,
obesity is the leading
modifiable risk factor
for the development
of CVD in women.
Screening is simple in
the clinical setting,
especially for
practices that use
the EMR as BMI is
automatically
calculated for you.
There is a dearth of
information on
clinicians not
addressing this
modifiable risk factor
in the clinical setting.
However, obesity
accounted for $147
billion in health
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spending in 2008 and
is expected to rise to
$244 billion per year
by 2018. The FRS
model has a separate
data base that
assesses CVD risk
that is based on BMI
and other nonlaboratory variables.

Prospective Studies
Collaboration 2009
Body-mass index
and cause-specific
mortality in 900,000
adults: Collaborative
analysis of 57
prospective studies

Level I Systematic
Review

Collaborative analysis
was undertaken of
baseline BMI versus
mortality in 57
prospective studies
in western Europe
and North America.
The analyses were
adjusted for age,
gender, smoking, and
study design. The
first five years of
follow up were
excluded, using an
additional eight years
of follow up analysis.

Mortality was lowest
in patients with BMI
levels of 22.5-25
kg/m². Each
additional 5 kg/m²
BMI was on average
associated with an
increased 30%
overall mortality
rate, 40% associated
with increased CV
mortality. At 30-35
kg/m² median
survival is reduced by
2-4 years and at 4045 kg/m² median
survival from a CV
event is reduced by
8-10 years.

Increased prevalence
of BMI ≥25 kg/m²
has been
consistently
increasing over the
years. Obesity is now
being observed in
childhood and
adolescence. There
have not been
studies following
childhood obesity
into adulthood for its
effect on morbidity
and mortality. This
modifiable risk factor
has a strong
associative effect on
the development of
CVD. The Nurse’s
Health Study
demonstrated that
women who gained
more than 25
pounds in weight
had a five-fold
increase for the risk
of hypertension.
Obesity plays an
increased CV risk in
multiple variables
such as
hypertension,
dyslipidemia and
Type II diabetes.

Ip, S., Lichtenstein,
A., Chung, M., Lau,
J., & Balk, E. 2009
Systematic review:
Association of lowdensity lipoprotein
subfractions with
cardiovascular
outcomes

Level I Systematic
Review

Data sources
included Medline,
CAB abstracts, and
Cochrane central
register of controlled
trials. Inclusion
criteria were
longitudinal studies
that reported an
association between
LDL subfractions and

Higher LDL particle
number was
consistently
associated with
increased risk for
CVD, independent of
other lipid
measurements.
Studies have not
determined whether
any measures of LDL

The ATP-III of the
Expert Panel of the
National Cholesterol
Education Program
has identified
elevated LDL
cholesterol as
pervasive CVD risk
factor. LDL
subfractions are a
myriad of additional
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Kim, J., Sillah, A.,
Boucher, J.,
Sidebottom, A., &
Snickelbine, T. 2013
Prevalence of the
American Heart
Association’s “ideal
cardiovascular
health” metrics in a
rural, crosssectional,
community-based
study: The heart of
New Ulm project

Level VI Cross
Sectional Study
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incidence of CVD.
Data was extracted
from 24 studies
which were
homogeneous in
terms of specific
tests analyzed,
analytical methods,
participants, and
outcome measures.

subfractions add
incremental benefit
to traditional risk
factor assessment.
There is limited data
from cross-sectional
and prospective
studies that further
analysis of LDL
cholesterol is a
better discriminator
of CVD risk.

tests what are
typically not covered
by insurance,
especially as initial
screening carried out
in the primary care
setting. The
recommended
screening continues
to be total
cholesterol, LDL,
HDL, and triglyceride
levels. This is the
lipid assessment that
will be run as part of
the EBP project.
Future research may
find LDL subfractions
as having greater
specificity for CVD
risk but the NCEP
guideline
recommendation
continues to be the
standard lipid panel.

The sample size
consisted of 4754
adults in New Ulm,
Minnesota that
participated in
community heart
health screenings in
2009 or 2011. 58.3%
of the participants
were women. Data
collected at the
screenings were
analyzed to replicate
the AHA ideal
cardiovascular health
measure. There were
seven metrics that
were evaluated:
smoking status, BMI,
nutrition, physical
activity, blood
pressure, blood
glucose, and
cholesterol panel.

Only 1% of the
participants met the
AHA’s definition of
ideal CV health in all
seven metrics. This
cross sectional design
had similar results to
other published
studies and appears
to be representative
of the U.S.
population.

These seven AHA
metrics are
significant for
evaluation of CV
health in the clinical
practice setting. It
has been reiterated
time and again that
CVD is multi-factorial
in nature. There is an
additive negative
consequence with
multiple risk factors.
It is imperative for
the practicing
clinician to apply a
validated CV risk
prediction tool in
asymptomatic adults
to evaluate CVD risk.
Achieving ideal CV
health lowers risk for
CVD, lowers
mortality rates, and
increased life
expectancy. CVD is
economically
burdensome with CV
related costs
comprising 17% of
the nation’s total
health expenditures.
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Note: Level I: Evidence from a systematic review or meta-analysis of all relevant randomized controlled trials
(RCT), or evidence-based clinical practice; Level II: Evidence obtained from well-designed RCT’s; Level III:
Evidence from well-designed controlled trials without randomization; Level IV: Evidence from well-designed
case-control and cohort studies; Level V: Evidence from systematic review of descriptive and qualitative
studies; Level VI: Evidence from single descriptive or qualitative studies; Level VII: Evidence from opinion of
authorities and/or reports of expert committees (Melnyk & Fineout-Overholt, 2011, p. 12)

Siontis, Tzoulaki, Siontis, & Ioannidis, (2012) compared cardiovascular disease
risk prediction models on their accuracy for prognostic prediction. Studies were included
that compared at least two different prediction models applied to the general population.
A total of eight risk prediction models were assessed for validity, reliability, and accurate
prognostic performance. The basis for the study was the opinion that practitioners need
reliable multivariate CVD risk assessment tools that can easily be utilized in the clinical
setting. Albeit limitations to the study were elucidated, the conclusion was that there was
no one risk prediction tool that was superior to another. The clinical usefulness of a risk
prediction model is its potential for affecting health care decision making and improving
health outcomes (Siontis, Tzoulaki, Siontis, & Ioannidis, 2012).
The Agency for Healthcare Research and Quality (Matheny, McPheeters,
Glasser, Mercaldo, Weaver, Jerome, Walden et al., 2011) completed a systematic
review of current CVD risk assessment tools applied in U.S. populations. The initial
search resulted in identification of 102 various risk models, however, 87 of these models
lacked validation. Of the remaining models assessed, the Framingham Risk Score
(FRS), Prospective Cardiovascular Münster (PROCAM), and the Systematic Coronary
Risk Evaluation (SCORE) were the tools most commonly reported in the literature. The
objective of the review was to assess risk models for the best prediction of
cardiovascular risk. The conclusion was that the FRS models performed well in U.S.
populations but concerns were raised regarding generalizability of the tool to diverse
populations. It was observed that when the FRS model was applied to a population that
was different from the original cohort, the risk prediction scores were not consistent. It
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was concluded that the newer models of the FRS performed better than the older
models and the gender specific models provided greater reliability. Additionally, all risk
prediction models demonstrated good relative and absolute risk prediction in the cohort
in which they were developed bringing into question the limitations of every risk
prediction model. Overall, the FRS models were deemed to be valid and reliable and a
favorable tool to use in clinical practice.
Hsu, Van-Khue, Ashen, Martin, Gluckman, Hohli, Sisson, Blumenthal & Blaha
(2013) in conjunction with John’s Hopkins and the American College of Cardiology
evaluated a global case control study entitled the INTERHEART Study, evaluating CVD
risk factors and creating an easy acronym to assist practitioners in clinical practice. This
Level IV evidence evaluated nine modifiable risk factors that are associated with >90%
of the risk for a first myocardial infarction (MI). The ABCDE approach which stands for
assessment of risk, antiplatelet therapy, blood pressure, cholesterol, cigarette smoking,
diet and weight, and exercise provides a guide for a consistent comprehensive approach
to cardiovascular risk assessment. This approach and recommendations which are
supported by evidence, provides a core framework for addressing CVD risk with the goal
of preventing CVD. The authors articulated the FRS model as being the most commonly
used global risk assessment tool. The authors did elucidate however, that in some
populations risk was underestimated by the FRS model. The authors compared the FRS
model with the Reynolds risk prediction tool. The Reynolds risk assessment adds family
history and CRP-hs data in its prediction model which are not included in the FRS
model. Application of the Reynolds risk score in the female population often reclassifies
their risk status to a higher level when compared to the FRS model. Ease of use in the
clinical setting and its consistent validation of reliability and validity still make the FRS
model an appropriate choice for CVD risk prediction. Cost considerations versus
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additional value of biomedical markers must be contemplated when initiating CVD risk
screening.
Cooney, Dudina, D’Agostino, & Graham (2010) in their systematic review
attempted to determine if CVD risk prediction as a primary prevention measure makes a
difference in clinical practice. The authors sought to appraise the evidence for the
rationale of estimating cardiovascular risk, compare the current CVD risk models for
clinical applicability, seek evidence for estimating CVD risk related to patient outcomes,
and determine the direction of CVD risk prediction in the future. According the authors,
to be clinically useful a CVD risk estimation model should be methodologically robust
and easy to use as well as address clinically relevant risk factors. A noted universal
limitation of all risk prediction models is the assumption that the effect of the risk is
constant, not taking into consideration age and level of degree of each of the identified
risk factors.
The authors assessed various risk prediction models for internal and external
validation as well as calibration. Calibration metrics for predicted to observed ratios
indicate values closest to one as being the best fit. Values >1 indicate overestimation
and values <1 indicative of underestimation. In a number of research studies, the FRS
models demonstrated calibration values between 0.76-0.86 (Cooney, Dudina,
D’Agnostino, & Graham, 2010). The FRS models have been modified over the years and
continue to be the most widely accepted and utilized models both nationally and
internationally. The FRS model remains the recommended assessment tool in both
national and international CVD prevention clinical practice guidelines.
The authors, due to a paucity of evidence, were unable to answer whether
identification of CVD risk makes a difference in patient outcomes. It is well agreed upon
that CVD is a multivariable disease and it is imperative to assess total risk versus
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identification and intervention of only single risk factors but additional research must be
rendered to answer the question posed by the authors.
The systematic review by Mosca et al. (2011) focused specifically on guidelines
for the prevention of CVD in women. The authors reviewed randomized controlled trials
(RCT’s) based on CVD prevention in women. One of the major findings discovered in
the review was a discerning escalation in CVD deaths in women between the ages of
35-54. The algorithm for risk stratification recommended three categorical levels of risk:
high risk, at risk, and optimal risk as defined by the number of CVD risk factors. Among
high risk, at risk, and optimal risk, the rates of MI, CVD deaths or stroke were 19.0%,
5.5% and 2.6% per ten years respectively (P for trend <0.0001) (Mosca et, al., 2011).
Because the lifetime risk for cardiovascular death in women is one out every two
women, it was determined through critical analysis of the literature, that the effectiveness
of prevention therapies did exhibit clinical benefit for improving CVD outcomes. By
establishing scientific levels of evidence and desired treatment strategies, guidelines are
fundamental in improving CVD preventive care. It was specified that applying evidencebased lifestyle modifications and interventions were the most cost-effective method for
CVD prevention.
The European Clinical Practice Guidelines authored by Perk et al. (2012)
disseminated recommendations on CVD prevention that should be both individual and
population focused. 1900 articles including RCT’s, meta-analyses, and non-randomized
control studies on risk assessment and CVD were evaluated using the AGREE
instrument. The guideline recommendations were rated based on the GRADE system
and are consistent with other reviews and guidelines in regard to modifiable risk factors.
Research supports the effectiveness of prevention strategies; 50% of reductions in CVD
mortality are related to changes in risk factors whereas, the World Health Organization
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(WHO) purports that greater than three-fourths of CVD mortality could be prevented by
lifestyle changes.
The authors analyzed the current literature and compared the FRS model with
the SCORE model demonstrating the estimation of risk as being comparable. A 5%
SCORE risk equated to a 10-25% Framingham risk corroborating the similarity of
outcomes in established risk prediction models (Perk et al., 2012).
It is essential for clinicians to be able to assess risk in a timely manner and with
sufficient accuracy to allow for logical management decisions in the practice setting.
Research and evidence-based clinical guidelines are an excellent mechanism for
improving the delivery of healthcare and improving patient outcomes.
Colagiuri, Tonkin, Harris, Briffa, Huang, Cary-Harzell, Azidi, et al. (2009)
published clinical guidelines for the assessment of absolute CVD risk. The objective of
the guideline was to assist health care professionals in assessing CVD risk in an
accurate manner in order to assist their patients in making well informed decisions about
clinical care management of the identified risks. The target population included adults
over the age of 18 without known CVD. The guideline authors sought to determine which
absolute risk assessment method is most predictive of future CVD events in a mixed
adult population not known to have CVD or diabetes. A search of the literature did not
specifically analyze the cost effectiveness of one assessment model over another. It was
reasonable to conclude, according to the authors, that there would be a realized cost
benefit that would result from implementation of an accurate risk prediction tool in
asymptomatic adults. The number one recommendation for intervention and practice
was to implement the FRS model for all adults ages 45-74 who are not known to have
CVD. Modeling studies provide the most compelling evidence that CVD risk assessment
in general practice is likely to improve CVD outcomes, compared with assessment and
treatment of single risk factors.
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Dyakova, Drew, Wright, Clarke & Rees (2013) through the Cochrane Heart
Group developed a protocol on CVD risk assessment as a primary prevention
intervention. The authors recommended systematic risk assessment versus
opportunistic risk assessment. Systematic risk assessment was defined as a screening
program that involves a pre-determined process for selection of people who are
systematically assessed for CVD risk in a primary care or similar setting. Opportunistic
risk assessment was defined as a CVD risk assessment occurring sporadically in a
primary setting which could include a primary care office, pharmacy, occupational health
department or in a small business. The review focused on the effectiveness of
comparing systematic (intervention) to opportunistic risk assessment (control) for
primary prevention of CVD. According to the NHS Health Checks program, a standard
assessment based on simple questions and measurements to identify the risk of CVD,
was deemed to be the most effective.
Greenland, Alpert, Beller, Benjamin, Budof, Fayad, & Foster, et al. (2010) in
conjunction with the American College of Cardiology Foundation (ACCF) and the
American Heart Association (AHA) published guidelines for the assessment of
cardiovascular risk in asymptomatic adults. The guideline objectives were to assist
healthcare practitioners in clinical decision making, to assist providers in the initial
assessment of risk in apparently healthy adults, and to provide a foundation for targeted
preventive efforts based on an individual’s predicted risk. These authors presented a
paradigm of care for the standardization for CVD risk assessment in this population. The
goal of early risk identification in asymptomatic individuals is to provide targeted
interventions to reduce or eliminate the identified risk factors. Cardiovascular disease
has a long asymptomatic latent period which provides an opportunity for early and
effective preventive interventions. The recommendation by the authors was for use of a
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global risk score, such as the FRS, that evaluates multiple traditional cardiovascular risk
factors.
Worrall-Carter, Ski, Scruth, Campbell, & Page (2011) authored a systematic
review of CVD risk in women, acknowledging the gender differences in CVD risk
significance. Risk factor modification is paramount for primary and secondary prevention
of CVD. Analysis of the Framingham Heart Study, of which 53% of the participants were
female, identified six main risk factors for CVD. The risk factors purported to be most
significant were blood pressure, lipids, smoking, diabetes, BMI, and physical inactivity.
The authors concluded that most CVD risk in women is modifiable and the key is
effective and relevant risk factor identification and early intervention.
The cardiovascular disease risk estimation and prevention summary authored by
Read (2012) and published by JBI confirmed the maxim that CVD has multiple risk
factors, of which the majority are modifiable. Moderate risk individuals constitute the
largest group of screened individuals and this population also has the highest rate of
mortality. The best practice recommendations in addition to advocating risk prediction in
asymptomatic adults were to focus on research evidence that supports positive
improvements in modifiable risk factors.
Murphy, Dhangana, Pencina, Zafar, & D’Agostino (2011) evaluated the FRS
model for its risk prediction capabilities. The model was evaluated using Receiver
Operating Characteristics (ROC) curves, sensitivity, specificity, and accuracy. There is a
strong positive association between the FRS prediction and the incidence of hard
coronary heart disease. The current Adult Treatment Panel III (ATP III) guidelines call for
intensive medical risk factor reduction in individuals identified at moderate or high risk by
the FRS model. There is no known trigger threshold with regard to an individual risk
factor; therefore individual risk factor management strategies are less than optimal for
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effectively lowering overall risk. It is imperative to implement comprehensive risk
lowering reduction in those individuals identified with multiple CVD risk factors.
McGorrian, Yusuf, Islam, Jung, Rangarajan, Avezum, & Prabhakaran et al.
(2011) applied the INTERHEART modifiable risk score to a multi-international
population. Summating risk factor burden is crucial in assessing CVD risk in apparently
healthy persons. As previously elucidated, the INTERHEART risk score assesses nine
modifiable risk factors that are estimated to account for more than 90% of the population
attributable risk. The benefit of using the INTERHEART risk score, as articulated by the
authors, included its applicability to a number of populations and ethnically diverse
cultures around the world. The variables assessed through this tool are time consuming,
costly and glean a significant amount of subjective data such as stress and depression
levels. The tool, albeit valid, would not easily be implemented into a busy clinical practice
setting.
Tattersall, Gangnon, Karmali, & Keevil (2012) compared the clinical impact of
replacing the FRS with the Reynolds Risk Score (RRS) in U.S. populations. Risk models
differ in variables, definitions of endpoints and the population in which they were
developed and validated. Both the FRS and the RRS have been validated in the U.S.
population. 1440 women who were analyzed with the FRS found 82% to be at low risk,
11.4% at moderate risk and 0.6% at high risk. In contrast, when using the RRS, risk
classifications were more severe (p<0.0001) with 76% at low risk, 11% at moderate risk,
9.3% at moderate-high risk, and 3% at high risk (Tattersall, Gangnon, Karmali, & Keevil,
2012). The magnitude and direction of change were more noticeable in women than in
men when comparing the models. In an effort to translate the differences in the models
to clinical practice, it was found that only a small percentage of individuals who had been
reclassified received different clinical recommendations regarding treatment of risk
factors.
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Clinicians have an increasing number of choices of which cardiovascular risk
prediction tool to utilize and how to determine the population effects of various
multivariate risk models compared to the well accepted FRS models. A practicing
clinician must choose a model that will be advantageous with the patient population and
applicable to the clinical practice setting.
As previously elucidated, there are a handful of modifiable risk factors that
account for 80-90% of all CVD morbidity and mortality, these modifiable CVD risk factors
will be discussed in the following section.
Smoking
Smoking both active and passive is a well-established vascular risk factor and
one which is prima facie to modify. Katsiki, Papadopoulou, Fachantidou, & Mikhailidis
(2013) in a narrative review, weighed the effects of various forms of smoking on CVD
risk. Although various forms of smoking all pose a CVD risk, cigarette smoking is
compellingly associated with morbidity and mortality. In a meta-analysis review, smoking
cessation was shown to significantly reduce CVD mortality (OR=0.54, 95% CI=0.460.62). A Cochrane systematic review found that smoking cessation was associated with
a significant (36%, OR=0.64, 95% CI=0.58-0.71) reduction in all case mortality. Smoking
can cause endothelial dysfunction, enhance platelet aggregation, and impair fibrinolysis,
increasing the prevalence and severity of thrombotic CVD events. Smoking interacts
with several other cardiovascular risk factors including hypertension, dyslipidemia, and
diabetes to significantly augment level of risk.
Hypertension
Al-Ansary, Tricco, Adi, Bawazeer, Perrier, Al-Ghanaim, Alyousefi, et al. (2013)
completed a systematic review of recent clinical practice guidelines (CPG’s) on the
management of hypertension. Eleven CPG’s were evaluated using the AGREE-II
assessment tool. There was disparity among the guidelines regarding levels of
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hypertension, when to initiate treatment, what treatment to initiate, and what the goal of
hypertension management should be. Regardless of the disparate recommendations in
the CPG’s, it was consistently recommended that blood pressure be assessed in
relationship to other cardiovascular risk factors during patient assessment.
A large systematic review of 147 clinical trials reporting on the management of
hypertension; showed that a mere reduction of 10 mm Hg in systolic blood pressure and
5 mm Hg reduction in diastolic blood pressure was associated with a 20% reduction in
coronary heart disease and 32% reduction in stroke in one year (Al-Ansary et al., 2013).
The FRS has authenticated the associative relationship between blood pressure and
cardiovascular risk as continuous and linear and consistent across age groups for
development of cardiovascular events. It has been estimated that 54% of all strokes and
47% of all ischemic heart disease is attributable to high blood pressure (Al-Ansary et al.,
2013). Despite the availability of CPG’s, optimal hypertension control remains an
intangible goal worldwide.
Obesity
Mohebi, Bozorgmanesh, Azizi, & Hadaegh (2013) assessed the effects of obesity
on coronary heart disease in women and the Prospective Studies Collaboration (2009)
analyzed 57 prospective studies on BMI and cause specific mortality. Epidemiologic
studies have found obesity (BMI ≥30 mg/m²) to be a conventional risk factor for coronary
heart disease. Cross-sectional associations between BMI and risk factors were
estimated by multiple linear regression or logistic regression with adjustment for study,
baseline age, and baseline smoking status. Increased BMI was associated with
increased blood pressure and abnormal lipids which are additionally both modifiable risk
factors for CVD. Mortality is lowest in in those individuals with an optimum BMI of 22.525 kg/m². For every 5 kg/m² higher BMI, there was an associated 30% higher all-cause
mortality (Mohebi, Bozorgmanesh, Azizi, & Hadaegh, 2013).
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Cholesterol
Ip, Lichtenstein, Chung, Lau, & Balk (2009) disseminated findings on a
systematic review evaluating the association of low-density lipoprotein with
cardiovascular outcomes. There is irrefutable evidence that high levels of total
cholesterol, low-density lipoprotein (LDL), and low levels of high-density lipoprotein
(HDL) are salient risk factors for cardiovascular disease. According to the authors, LDL
cholesterol is influential in enhancing CVD risk. LDL cholesterol is not taken up by the
cells, staying in the blood stream and creating foam cells which causes inflammation and
increases risk for ischemia and hypertension. It is estimated elevated cholesterol
fractions account for greater than 50% of all cardiovascular events. Dyslipidemia is yet
another CVD risk factor considered to be a modifiable risk factor.
Kim, Sillah, Boucher, Sidebottom, & Knickelbine (2013) in a cross-sectional study
assessed for ideal cardiovascular risk in a rural community in Minnesota. The delineation
of ideal cardiovascular risk as defined by the American Heart Association includes seven
modifiable metrics for assessing cardiovascular health. These ideal metrics include
blood pressure, cholesterol levels, smoking status, physical activity, BMI, dietary intake,
and blood glucose. The researchers gathered data in a cross-sectional cohort over a
period of two years. SPSS statistical analysis using a two-sided α considered statistical
significance to be 0.05. Pearson x² tests were used for comparisons of age and sex.
Attaining ideal cardiovascular health in this study was extremely low (1%), however
achievement of ideal cardiovascular health metrics would notably decrease CVD burden
and associated health care costs.
Synthesis of the critically appraised literature
Current relevant literature provides a superlative perspective of cardiovascular
disease burden both physically and economically as it affects the female population. The
literature is consistent in identification of modifiable risk factors that account for >80-90%
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of the disease burden. The appraised literature is replete with the recommendation and
significance of cardiovascular risk screening in asymptomatic adults as well as the
deficiency in screening currently observed in the clinical practice setting. Risk
assessment algorithms may be used to identify modifiable risk factors, raise awareness
of CVD, educate, prompt risk modification, and predict both short and long term risk of
developing CVD.
The goal of early CVD risk identification in asymptomatic adults is to provide
targeted interventions to reduce or eliminate the risk and change the trajectory of CVD
progression. Summarization of the current evidence, as reported in the literature by
experts in the field of cardiovascular disease, deduced that many risk prediction models
are reliable and valid but that all models have limitations. All of the validated models
assess for a core number of modifiable risk factors including blood pressure, smoking
status, blood glucose, lipid analysis, physical activity, and BMI. Many of the models,
especially the European models, assess for additional risk factors such as depression,
anxiety, socio-economic factors as well as additional biologic markers such as CRP-hs
and additional lipoprotein analysis.
The goal in CVD prevention is to produce the largest relative risk reduction, the
smallest number needed to treat, and the lowest cost per quality-adjusted life year saved
(Ashen, 2010). To be clinically relevant, a risk prediction model must be robust and must
be clinically applicable considering the patient population, practice setting, time
constraints, cost, and objective for implementing a CVD risk prediction model in the
clinical setting. In clinical practice, risk prediction algorithms have been used most
directly to identify individuals at risk for developing CVD and institute interventions to
reduce morbidity and mortality of the disease. The 16 high level of evidence summaries
all substantiated the use of the FRS model as a universally accepted risk prediction
model in the U.S. and recommended its use as a primary prevention measure. This DNP
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project manager employed the FRS model to the identified study population with
resultant findings to be discussed in-depth in chapter three.
Construction of the EBP project
Intertwining Pender’s health promotion model and Stetler’s evidence-based
model with rigorous integration of current evidence provides a cogent foundation for this
evidence-based practice project. The detailed implementation process will be discussed
throughout the project paper.
Best practice recommendation
Risk scores can be useful educational and motivational tools for patients. The
best practice model is one that is implemented by practicing clinicians and employs
primary prevention performance guidelines for assessment of CVD risk in the
asymptomatic patient utilizing a multivariate risk model. This DNP project manager has
the knowledge and clinical expertise to implement the risk assessment screening tool in
the identified practice setting. The best practice recommendation is one that is valid and
reliable and is applicable to the constructs of the PICOT question. The Framingham risk
score (FRS) model was chosen for this EBP project for its ability to consistently predict
risk assessment in asymptomatic women.
Answering the clinical question
The best practice recommendation answered the clinical question: In women
ages 35-50 presenting for their annual gynecologic exam and are asymptomatic for
CVD, how does implementation of the FRS compared to usual care (no screening),
identify the level of CVD risk over a three month period of time? The DNP project
manager negotiated with the practice manager and CEO regarding the implementation
process and the need for provider and staff buy-in. The DNP project manager initiated
strategies with the staff regarding the significance of gleaning CVD risk prediction data.
In concordance with the Lifestages mission statement which includes advocating for,
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development of, and implementation of quality, comprehensive, and cost effective health
care programs which educate, inform and support women in making their health care
choices and in living healthful lives was repeatedly reiterated to the identified
stakeholders. The DNP project manager reinforced the vision of the practice which is to
provide comprehensive health care across the lifespan with uniform excellence in quality
and service. The DNP project manager educated the clinical staff on the scope of the
problem, procuring the informed consent, on garnering the required metrics, and on the
process of appropriating the completed data to the DNP project manager. The DNP
project manager inputted data into the web based FRS prediction tool and elicited risk
stratification for each person in the EBP project. Statistical data analysis was computed
using the SPSS 20 statistical analysis program.
Inclusion of the clinical staff in study purpose and significance, data gathering
and education promotes team work and a sense of accomplishment. Staff realization
that they were being influential in the potential improvement in health outcomes of the
patients they serve provided a sense of worth and a feeling of making a difference
versus only performing a job.
Dissemination of study results were shared with the clinical staff as well as with
individual patients on follow up appointment. Enhanced collegiality among the provider
staff was procured through diffusion of the EBP project findings. Further dissemination of
clinically relevant data was accomplished through scholarly publication, community
educational presentations, and through local and national professional organizations.

SCREENING CARDIOVASCULAR RISK

52

CHAPTER 3
IMPLEMENTATION OF PRACTICE CHANGE
Evidence based practice is the salient commitment to the implementation of
theory-derived and research-based evidence in making critical thinking decisions
regarding provision of health care. It is not enough to have knowledge of the best
evidence to guide clinical practice; that knowledge must be translated into clinical
practice to improve patient care and outcomes (Hockenberry, Brown, & Melnyk, 2011).
The method used for the design and implementation of the EBP project will be discussed
in detail in this chapter. Amalgamation and management of data as well as protection of
human subjects will also be discussed.
Sample/Setting
The EBP project participants originated from a convenience sample of women
who met inclusion criteria and provided informed consent to participate. In a
convenience sample the inclusion criteria is identified prior to selection of project
participants and all persons who meet the inclusion criteria are welcomed to participate
(White, 2012). Because the sample is selected for ease of data collection, this sample
may not be representative of the target population. This may well be the case in the
instance of this EBP project as the office setting chosen, again due to ease of project
implementation, is only one of five office settings for this OB/GYN practice. The
probability for bias is high in a convenience sample as again it may not be representative
of the target population. Strategies to control for bias were utilized such as comparing
demographic data from individuals in the EBP project to general population
demographics to determine if the project sample is representative of the general
population.
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Lifestage’s Centers for Women has five practice settings located in southern
Ohio. The provider staff of Lifestage’s consists of eight OB/GYN physicians, four certified
nurse midwives (CNM), and one board certified family nurse practitioner (FNP). On any
given work day, there can be anywhere from two to four medical providers working in the
EBP project implementation clinical practice site. Lifestage’s offices are diverse in both
their location and the populations they serve. Of the five practice sites, one is located in
an affluent upper class area of the region, two are located in inner city lower income
areas, another in a low to middle class environment and the fifth practice setting is
located in a middle to upper class area of the city.
The practice setting that was utilized for this EBP project is located in an upper
middle class neighborhood which is easily accessible via a major highway, has ease of
parking, and is also adjacent to a city bus route. The clinical practice site is located
within a large multi-faceted outpatient facility. Many patients take advantage of this
location for its accessibility and functionality. Because of the myriad of services available
in this outpatient facility, many patients take advantage of this setting because they can
consolidate other testing such as mammography and laboratory testing in conjunction
with their medical appointment. This location is an encashment area for several smaller
communities that surround the facility therefore providing a wide diversity of population
demographics. Among the smaller communities that predominantly employ this
outpatient setting are small farming communities, a large German Baptist community,
and small communities that extend toward the Richmond Indiana area.
Design
The purpose of the EBP project was to implement cardiovascular disease risk
assessment screening using the Framingham Risk Score (FRS) model in asymptomatic
women to identify and stratify their level of CVD risk. The EBP project is designed as a
primary prevention intervention. The tacit goal of primary prevention is the attempt to
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prevent disease from occurring. Primary prevention therefore reduces both the incidence
and prevalence of a disease. CVD is particularly suited for application of primary
prevention because it is common, occurs at a high incidence, can be modified by
behavior, has a long latency period, incurs high financial costs, and has a high societal
burden (Ashen, 2010). The health care arena has traditionally focused on secondary and
tertiary levels of prevention, the foci being on treating disease once it has occurred
rather than preventing it from occurring. Compelling evidence exists garnering the
importance of primary disease prevention as it relates to CVD in women. Cardiovascular
disease risk assessment and stratification can theoretically raise population and
individual awareness of disease and motivate changes in behavior to improve health and
health outcomes as well as decrease the economic burden of CVD.
Strategies for education and dissemination of information regarding the EBP
project included PowerPoint presentations, e-mail communication, role playing, and a
scripted module for the medical assistant to employ while explaining the EBP project to a
potential project participant. The DNP project manager developed two PowerPoint
presentations, one that was specific to the provider staff and practice administrators and
one specific for the medical assistant and R.N. staff. The PowerPoint presentations were
presented to and approved by the CEO and the office practice manager prior to
dissemination to the staff.
The PowerPoint presentation for the medical provider staff was presented at the
monthly provider meeting and included CVD background and significance, evidence and
research related to CVD risk prediction, practice mission and vision statements, EBP
project objectives, and implementation process. Time was allotted for feedback, critique
and questions regarding the project and its implementation.
The PowerPoint presentation was presented to the office staff, including MA’s,
RN’s, practice manager and office manager, at their monthly meeting which included
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CVD significance and background as well as an outlined step by step methodology for
the MA role in the project implementation. A script was prepared for the MA’s which
presented a dialogue to incorporate into the patient interview process, therefore
providing a consistent procedural methodology in which to communicate and interact
with potential EBP project participants. Role playing was incorporated into the
presentation agenda in which the MA’s simulated an interaction with a potential project
participant. The role playing module addressed various scenarios and potential
questions that an EBP project participant may have. During the role playing activity,
brain storming and suggestions were made by those observing the role play interaction.
Additional presentations were scheduled over lunch hours and before and after office
hours to capture those absent from the aforementioned meetings.
A bulleted laminated step by step protocol was provided to the MA’s and was
also made available in the work station and provider offices, to quickly ascertain
inclusion criteria and applicability for participation in the EBP project. The DNP project
manager sent frequent email reminders regarding the EBP project and encouragement
to be participative in recruiting applicable project participants. Access to the DNP
manager included in-basket computer communication as well as phone communication.
When the DNP project manager was working at the implementation site, she was
available for face-to-face questions or concerns and would make contact with the
medical assistant several times throughout the work day.
The DNP project manager identified inclusion criteria for potential EBP project
participants to include a convenience sample of women between the ages of 35-50 who
did not have a diagnosis of cardiovascular disease, in other words, were not being
treated for dyslipidemia, hypertension, or type II diabetes. The sample consisted of
women who presented to the Samaritan North office of Lifestage’s Centers for Women
for their annual preventive gynecologic exam.
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The screening process was delineated in a step by step process for the medical
assistant staff as well as the provider staff. When the MA arrived for the day, she printed
out the schedule of the provider that she would be working with that day. The MA then
looked at the ages of the patients and identified those who fell into the 35-50 year old
age range. She then looked at the visit type and identified those women who were
scheduled for their annual preventive exam versus an acute problem or a pre-op patient.
The MA then notated next to the patient name, with an asterisk, that this patient met
initial inclusion criteria. Before the patient arrived, the MA checked the patient chart for
diagnosis of hypertension, dyslipidemia, or type II diabetes that would exclude them from
participating in the EBP project. If the patient met all of the inclusion criteria the MA
offered CVD risk screening to the patient during the interview process using the scripted
dialogue that was presented during the role playing portion of the staff meeting. Using a
standardized script, the MA explained briefly the significance of CVD in women, goals
and objectives of the EBP project and if the patient consented, what the process would
entail for the patient. If the patient desired to participate, the MA obtained a signed
informed consent form. The informed consent form contained the elements of the title of
the project, aim/purpose of the project, the DNP project manager information, risk/benefit
to the patient, assurance that all patient information would be held in strict confidentiality,
and that participation in the EBP project was voluntary and without monetary
compensation. It was also articulated to the patient that she would be responsible for
any laboratory co-pays or fees. Ascertainment of understanding was elucidated and any
questions were answered, after which the patient signed the consent form. Once the
patient signed the informed consent form, the MA apprized the medical practitioner of
the patients’ consent to participate in the EBP project. During the patient exam, the
medical practitioner reinforced the significance of CVD risk assessment in women and
the objective of the EBP project, answered any questions that they may have had, and
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ordered the fasting laboratory testing consisting of a comprehensive metabolic panel
(CMP) and a lipid panel. The laboratory testing was ordered for the patients’ laboratory
of choice or laboratory that was deemed appropriate by the insurance carrier. The MA
completed the data entry form and attached it to the consent form and placed them in a
folder in the nurses work station for the DNP project manager to collect (Appendix A&B).
The DNP project manager collected the forms on a daily basis and procured them in a
secure location to maintain patient privacy and confidentiality.
The DNP project manager frequently queried lab results for patients who had
consented to project participation. Once the laboratory testing was complete, the DNP
project manager entered the data into the FRS model database and obtained risk score
results which were printed out in duplicate. One set of the results were scanned into the
electronic medical record (EMR) and the other was maintained by the DNP project
manager to input into the SPSS-20 statistical program.
Once the data had been collected and inputted into the FRS model and risk
identification has been gleaned, the DNP project manager made the determination
whether or not the patient required a follow up appointment. Those individuals who had
identified CVD risk were notified by the R.N. to make a follow up appointment with the
FNP, the patient’s primary care provider, or for cardiology referral to review the FRS
results and adjudicate a plan of care.
In tandem with the clinical practice marketing director a thank you letter was
drafted and approval by the CEO and practice manager which was then mailed out to
each EBP project participant. The letter thanked the participant for being proactive in her
CVD health and included a red dress pin, a hallmark identifier for CVD awareness, as
well as a print out of her FRS model data with interpretation. A total of three letters were
drafted, one for normal risk factors, another for abnormal risk factors requiring a follow
up appointment, and a third letter informing the patient that the laboratory testing was

SCREENING CARDIOVASCULAR RISK

58

normal but that BMI is elevated and offering suggestions that may assist the patient in
reducing BMI (Appendix C, D, & E).
The marketing director interviewed the EBP project manager for an article in the
quarterly Lifestage’s newsletter that is available on the practice web site, available in the
office, as well as a direct mass mailing to the community. The marketing director is also
responsible for setting up health talks within the community and has involved the DNP
project manager as a speaker on CVD as it relates to women in a variety of community
venues.
A strong commitment exists within the practice and with the medical practitioners
to have ongoing assessment of CVD risk in women. The outcome data from the EBP
project provided compulsory evidence supporting the need to screen asymptomatic
women for CVD risk and rendered credence to the need for a permanent clinical practice
change. It is imperative to continue to provide credible data, education on the
significance of CVD risk as it pertains to the female population, and emerging trends in
CVD risk prevention to improve the health of women.
Instrument
Accurate and timely risk estimation and identification of individuals at increased
risk for CVD is the cornerstone of CVD prevention. Clearly, risk prediction models must
be based on statistically sound methods and should accurately estimate risk in the
sample population. The ability to accurately assign individuals to categories of risk where
the observed rate of disease correlates to the risk prediction is evidence of a valid risk
prediction model. Clinical risk profiling is recommended by clinical practice guidelines as
a foundational beginning for the evaluation of asymptomatic individuals in identification
of CVD risk level.
The Framingham risk assessment model was the instrument utilized to
prognosticate CVD risk in this EBP project. The concept of risk factors for CVD
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identification, introduced by the Framingham Heart Study, serves as the gold standard
for CVD risk assessment. The Framingham risk score is a multivariable mathematical
risk equation that predicts a 10-year risk of developing CVD events. In addition to
determination of 10 year risk levels, the FRS model also delineates vascular heart health
age based on risk factor stratification as it compares to chronological age. For example,
based on risk factors, a 59 year old female may have the heart health age of a 48 year
old or vice versa. This delineation may provide a greater significance and understanding
for the individual patient versus a 10 year risk percentage number.
The Framingham Heart Study remains the most famous and influential
investigation in CVD epidemiology, and since its inception in 1947, has garnered over
2000 peer reviewed articles (Oppenheimer, 2010). The Framingham Study has provided
insights into the prevalence, incidence, prognosis, predisposing factors, and
determinants of CVD. The scientists involved with the Framingham Heart Study were
instrumental in changing the concept of chronic disease into discernment of probability
and disease prevention. Through population based randomized controlled trials and
observational cohort studies in diverse population samples, the researchers associated
with the Framingham Heart Study were able to effect change in how clinicians
approached CVD as well as the efficacious applicability of primary prevention.
The metrics assessing the parameters of a risk prediction model must evaluate
its ability to discriminate future cases from non-cases, determine the ability of the model
to inform regarding the outcome of interest, and the calibration of the model related to its
validity and reliability (Llyod-Jones, 2010). The most widely reported measure of model
discrimination for CVD risk prediction models is the C statistic. The C statistic is a
function of both the sensitivity and specificity of the model across all of its values, and it
represents the ability of the score to discriminate cases from non-cases (Llyod-Jones,
2010). In simplistic terms, the C statistic indicates the probability that a randomly
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selected individual who develops disease would have a higher risk score than a
randomly selected individual without disease. The C statistic can vary from 1.0, which is
perfect discrimination, to 0.5 which is equivalent to random chance. C statistics between
0.70 and 0.80 are considered to be acceptable and those that fall between 0.80 and 0.90
are considered to be excellent (Lloyd-Jones, 2010). A combination of multiple
independent risk markers, as in the Framingham risk score model, provides magnitude
of relative risk and C statistics that typically range from 0.75 to 0.80. The Framingham
risk score model discriminates risk better for women than men with C statistics that are
generally >0.80 for women (Lloyd-Jones, 2010). Measures of calibration assess the
ability of a risk prediction model to predict accurately the absolute level of risk that is
subsequently observed. For example, if a risk prediction model is well calibrated an
observed event rate would be similar to the level of risk identified by the model, so if an
individual has a 7% risk of a CVD event over 10 years, the observed event rate should
also be close to 7%. Other measures such as likelihood ratio tests and the Bayes
information criterion are commonly used to assess the utility of risk prediction models.
These tests when statistically significant can indicate whether a risk model is predicting
disease incidence better than by chance alone (Lloyd-Jones, 2010).
The literature review has been succinct in identification of significance and
variance of risk factors as they pertain to gender differences in CVD risk. Although the
classic risk factors are the same for women and men, there are gender differences in the
prevalence and significance of the various risk factors. The clustering and
interrelationship of multivariate risk factors exhibit different risk levels based on gender.
The Framingham risk score model has a gender specific score model which enhanced
its applicability in the identified EBP project population.
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Measurement
The Framingham Heart Study generated seminal findings such as the effects of
tobacco use, unhealthy diet, physical inactivity, obesity, hypertension, dyslipidemia, and
diabetes on the development and progression of CVD (Mendis, 2010). The Framingham
Risk score model, using a sex specific multivariate risk factor algorithm, was used to
assess CVD risk for each individual EBP project participant. Electronic calculator web
based data analysis was completed on each EBP project participant. The data was
inputted into both of the gender specific FRS models, which included the laboratory data
base and the body mass index (BMI) data base (Appendix F & G).The FRS spreadsheet
provides a rapid visualization of the gleaned data including percentage of risk over a 10
year period of time as well as each individuals estimated vascular or heart age. Each
data spreadsheet was printed and scanned into the patient EMR where is can easily be
accessed by the patient’s team of medical providers.
Outcomes
Data analysis is “the process of breaking down, examining, comparing,
conceptualizing, and categorizing data” (Mauk, 2012). Once the intervention has been
implemented it will be imperative to evaluate the effectiveness of the intervention.
Rigorous analysis of the project outcomes must be corroborated with the EBP project
goals and objectives as well as the PICOT question. Questions must be propagated
regarding outcome achievement and analysis of all possible factors that may have
impeded the desired outcome if the EBP project objectives were not met. Initiatory
outcomes demonstrated a significant percentage of women who had identified CVD risk
factors and required additional follow up. A meticulous analysis of the data will be
articulated in detail in Chapter four.
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Implementation of practice change
It is imperative to be cognizant of and anticipate potential barriers to changing
clinical practice, among these conceivable barriers are organizational culture, belief
systems, and research related barriers (Young, 2012). The word change evokes a
myriad of defining characteristics which can be quite disparate from one individual to
another. Some individuals view change as positive and challenging where others may
view change as negative and a divergence from the status quo. Identifying strategies to
implement change in a positive manner will be the catalyst to making a smooth transition
to a new clinical practice paradigm. Applying a simplistic change model such as Kotter’s
eight change phase’s model in conjunction with the Stetler model of EBP will promote a
venue for a positive change transition. The eight change phases include creating a
sense of urgency; creating a guiding coalition; developing a change vision;
communicating the vision; empowering broad-based action; generating short-term wins;
don’t let up; and make it stick (Kotter,1996).To lead change successfully Kotter and
Schlesinger (2008) recommend analyzing situational factors, determining the optimal
speed of change, develop methods to manage resistance, educate, communicate,
encourage participation, negotiate, facilitate and support. The reader may refer back to
chapter two for in depth detailing of the foundational models.
When evaluating the outcomes of an EBP implementation, it is important to
realize that EBP fosters common goals such as improved patient care and best practice
through interdisciplinary collaboration (Fineout-Overholt, Melnyk, & Schultz, 2005).
Providing EBP project outcome data to the practitioners and staff in the clinical setting
will garner collegiality and support among the entire staff and modulate a clinical practice
change. The goal of implementation of the EBP project is to generate outcomes that will
support the need for a best practice clinical practice change. By sharing knowledge,
evidence, research, and outcomes, EBP guidelines can influence consistency and best
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practice in the clinical practice setting. Demonstration of significance will support the
need to make CVD risk prediction screening a clinical practice change to both align with
the mission and vision of the practice as well as a commitment to improve the health of
the women we care for.
Not only does an EBP clinical practice change affect the clinician’s practice
behavior but it also unequivocally affects the patient. Dissemination of risk findings must
be communicated in a manner that will make an impact with the patient. Evidence-based
practice is based on the three components of research-based knowledge, clinical
expertise, and patient preference and needs. Patient preference is perhaps the most
challenging component of the EBP process. As a clinician, developing a partnership with
the patient is prima facie to the success of sharing information and being instrumental in
partnering with the patient to mitigate positive health behavior changes.
Applying Pender’s Health Promotion Model as a foundation for the EBP project
facilitates identification of the motivation in individuals that will promote a behavioral
change as well as potential barriers that inhibit adapting positive health practices. When
Pender’s HPM is implemented in clinical practice, it can be an efficacious tool in
increasing patient awareness of their risk factors and facilitating movement toward
positive health practices and improved health outcomes. As previously elucidated, the
FRS model will determine 10 year risk of developing a cardiovascular event but will also
report a person’s heart age based on obtained metrics. This knowledge may be more
tangible and motivating for an individual to make healthy lifestyle changes than a 10 year
risk percentage number that may be difficult for the patient to conceptualize. Aggressive
primary prevention in asymptomatic women is crucial in reversing the ominous trend of
CVD morbidity and mortality.
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Management of data
Continuous variable dichotomization is a popular technique used in estimation of
the effect of risk factors on health outcomes in multivariate regression settings. The
validity and reliability related to the prognostication of the FRS model has previously
been discussed. Measurement of the impact of the EBP project primary prevention
intervention was analyzed by descriptive and inferential statistics using the SPSS 20
statistical program. Descriptive statistics and frequencies were used to describe the
demographic data of the project sample. Correlational relationships between variables
further delineated significance of modifiable risk factors. One of the initial identified
deterrents to completing the screening was the need for laboratory testing to be done
with the patient fasting. The FRS model has two gender specific databases, both which
are inclusive of age, smoking status, and blood pressure. In addition to the above
mentioned variables, one database uses laboratory testing and the other uses BMI
instead of laboratory testing. This BMI version of the FRS model may be easily
implemented in the clinical practice setting where there may be logistical constraints
such as lack of readily available laboratory settings or where compliance may be an
issue. Further discussion related to EBP project implementation weaknesses and
strengths will be considered in Chapter five.
Protection of human rights
Institutional review board approval was received by Valparaiso University and
approval for the EBP project was obtained from the clinical practice site administration
prior to implementation of the EBP project. Expedited review was obtained based on
minimal risk to the patient and significant potential for positive benefit gleaned from the
EBP project.
Strict confidentiality was maintained throughout the EBP project. Personal data
and demographics were maintained in a secure locked file in the practice setting and
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CHAPTER 4
FINDINGS
The purpose of the EBP project was to screen asymptomatic women between
the ages of 35-50 to identify modifiable CVD risk factors as well as their level of CVD
risk. This EBP project was implemented in the clinical practice setting of a large
women’s health practice in Southern Ohio. The clinical question in PICOT format was: In
women between the ages of 35-50 presenting for their annual gynecologic preventive
exam, who are asymptomatic for CVD, how does implementation of the Framingham
Risk Score (FRS) model, compared to usual care (no screening), identify the level of
CVD risk over a 3 month period of time? The intended outcome of this primary
prevention EBP project was to identify and stratify CVD risk factors in asymptomatic
women, in other words women who are not being treated for hypertension, dyslipidemia
or type II diabetes. Identification of CVD risk in asymptomatic women allows for early
intervention to reverse risk factors and change the trajectory of CVD development. The
outcomes and data analysis of this primary prevention EBP project, which addresses the
clinical question, will be promulgated in this chapter.
Demographic data was collected on 148 participants who agreed to participate in
the EBP project and signed the consent form. The descriptive demographic metrics that
were gleaned included age, race, marital status, employment status, insurance status,
smoking status, and family history of CVD in a first degree relative at or before the age
of 55. These variables were obtained by the medical assistant (MA) at the time of the
patient appointment and were recorded on the patient data form.
Sample characteristics
All of the EBP project participants were female (n=148) between the ages of 3550. The mean age was 42.93 (SD = 4.73). Age distribution is visually depicted below in
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Figure 4.1. Age frequencies were fairly well distributed across the age range with the
exception of age 39 which consisted of only two participants.
Figure 4.1 Age Distribution n=148

Of the 148 women who signed consent forms to participate in the EBP project,
109 completed the laboratory testing, accounting for 73.6% of the original cohort. Table
4.1 visually depicts the characteristics of the sample who completed the laboratory
testing (n=109). Ethnic demography was comprised of 79.8% Caucasian, 18.3% African
American, and 1.8% Asian women. Among marital status 66.1% were married, 10.1%
divorced, and 23.9% were single. Of those who identified themselves as single, it was
not ascertained if they were single never married or defined themselves as single due to
divorce. The majority of the women were employed, 85.3% while 14.7% were
unemployed. The status of employment was undeterminable in regard to employment
status being full time, part-time, or prn status. Insurance status included 80.7% of study
participants who had commercial insurance, such as United Healthcare, Aetna, or
Anthem, 14.7% were on Medicaid and 4.6% were uninsured. None of the study
participants were on Medicare insurance.
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In the sample completing the laboratory testing, 14.7% were smokers, 75.2%
were non-smokers, and 10.1% were former smokers. Unfortunately there is neither data
available regarding the amount of cigarettes smoked per day or the duration of smoking
history.
There is strong epidemiologic evidence for the familial aggregation of CVD and
the researchers from the Framingham Heart Study reported that having CVD in at least
one first degree relative increased the risk of CVD in women by 70% (Imes & Lewis,
2013). A positive family history of CVD in a first degree relative prior to the age of 55
included 36.7% of women while 63.3% of the project participants did not have family
history of early CVD. This subjective data may be biased as some participants may be
unclear as to what defines CVD and may not be fully apprised of the extent of their
family history.
A comparison of demographic characteristics was effectuated with those who did
not complete the laboratory testing (n=39) and these results are depicted in Table 4.2.
The demographic comparison was generated to determine if those who did not complete
the laboratory testing were similar in characteristics to the cohort sample that did
complete testing. Of the n=39 who did not complete testing, 82.1% were Caucasian,
15.4% African American and 2.6% Asian. The majority were married, 66.7% with 10.3%
divorced and 23.1% single. 76.9% of this sample were employed with 23.1% being
unemployed. The majority of these women had commercial insurance, 79.5% while
15.4% had Medicaid and 5.1% were uninsured. None of this cohort of women had
Medicare insurance. Non-smokers constituted 82.1% of this group, 15.4% were
smokers, and 2.6% identified themselves as former smokers. A positive family history of
CVD in a first degree relative at or before the age of 55 was depicted in 28.2% of this
population while 71.8% did not have this history.
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The demographics of the cohort sample that followed through with the CVD
screening were similar to those who did not complete the testing. These similarities are
germane in providing strength to the generalizability of the EBP project findings to the
general population. One comparison of interest to note was that more women who
completed the testing were employed (85.3%) compared to those women who didn’t
complete the testing (76.9% employed) demonstrating the largest variance in
demographic data.
Table 4.1
Sample characteristics of women completing the laboratory testing n=109
Trait________________________________________________Frequency (n) results_________
Gender

100% female (n=109)

Ethnicity

79.8% Caucasian (n=87)
18.4% African American (n=20)
1.8% Asian (n=2)

Marital Status

66.1% married (n=72)
10.1% divorced (n=11)
23.8% single (n=26)

Employment Status

85.3% employed (n=93)
14.7% unemployed (n=16)

Insurance

80.7% commercial (n=88)
14.7% Medicaid (n=16)
4.6% uninsured (n=5)

Family History of CVD before age 55

36.7% yes (n=40)
63.3% no (n=69)

Smoking Status

14.7% smoker (n=16)
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75.2% non-smoker (n=82)
10.1% former smoker (n=11)

Table 4.2
Sample characteristics of the women not completing laboratory testing n=39
Trait

Frequency (n) results

Gender

100% female (n=39)

Ethnicity

Caucasian 82.0% (n=32)
African American 15.4% (n=6)
Asian 2.6% (n=1)

Marital status

Married 66.7% (n=26)
Divorced 10.3% (n=4)
Single 23.0% (n=9)

Employment status

Employed 76.9% (n=30)
Unemployed 23.1% (n=9)

Insurance status

Commercial 79.5% (n=31)
Medicaid 15.4% (n=6)
Uninsured 5.1% (n=2)

Family history of CVD before age 55

Yes 28.2% (n=11)
No 71.8% (n=28)

Smoking status

Smoker 15.4% (n=6)
Former smoker 2.6% (n=1)
Non-smoker 82.0% (n=32)
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Changes in outcomes: statistical testing and significance
The interval variables assessed included systolic blood pressure (SBP), diastolic
blood pressure (DBP), total cholesterol (TC), triglycerides (TG), LDL cholesterol, HDL
cholesterol, blood sugar, and BMI. These variables with their frequencies are delineated
in Table 4.3. Although the aforementioned variables were assessed and are considered
individually and collectively as CVD risk factors, only systolic blood pressure (SBP), total
cholesterol (TC), HDL cholesterol, blood sugar, smoking and age are considered in the
laboratory FRS prediction model. Age, smoking, SBP, and BMI are considered in the
BMI arm of the FRS model. The FRS models are gender specific. The measures of
central tendency will be articulated in the following section.
Systolic blood pressure is considered normal if ≤140 mg/Hg. The spectrum of
systolic blood pressure readings ranged from 98 to 152 with a mean of 121.68
(SD=11.32). Of the 109 EBP project participants 6% exhibited systolic blood pressure
readings above the normal. Normal diastolic blood pressure is considered to be ≤90
mm/Hg. The array of readings ranged from 60 to 110 with a mean of 77.76 (SD=8.16)
with a resultant 16% of the EBP project participants having reading ≥90.
Normal total cholesterol level recommendation is ≤200. The range notated in the
study was 121-281 with a mean total cholesterol of 188.44 (SD=33.42). Of the 109
project participants, 38% had total cholesterol scores of ≥200. Triglycerides (TG)
guidelines recommend the level to be ≤150. The readings of TG’s ranged from 32-373
with a mean of 103.56 (SD=64.16). 20% of the project participants had TG levels that
were ≥150. HDL cholesterol is the cholesterol that exerts a cardio-protective effect if the
levels are ≥40. The range in the EBP project participants ranged from a low of 36 to a
high of 118 with a mean of 59.42 (SD=16.24). Of the 109 project participants 12%
exhibited levels of HDL that were ≤40. LDL cholesterol plays a major role in the
development and progression of CVD. The accepted range for LDL cholesterol is ≤100
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unless a patient has co-morbidities such as hypertension or type II diabetes, which then
LDL cholesterol is recommended to be less than 70. The range in the EBP study
population was 40-204 with a mean of 108.46 (SD=32.03). Data analysis demonstrated
58% of the project participants garnering LDL levels ≥100. Normal fasting blood sugar
should be ≤100, the EBP project range for blood sugar was 77-169 with a mean of 92.34
(SD=12.46). 20% of the participants demonstrated a blood sugar that was ≥100.
A normal BMI is considered to be ≤24.9, overweight 25-29.9, obese 30-34.9 and
morbid obesity ≥35. The range observed with the EBP project participants ranged from
19.69-54.03 with a mean of 30.06 (SD=7.00). 23.9% of the study population had a
normal BMI of ≤24.9; 30% of the cohort had BMI’s that fell between 25-29.9; 22.2% had
BMI’s between 30-34.9; and 23.9% demonstrated a BMI of > 35.
Prognostication of CV risk has historically been disparate among leaders in CV
health and risk assessment. The most current recommendation as acceded to by the
American College of Cardiology, the American Heart Association, and the researchers
from the Framingham Heart Study categorizes women as being at ideal CV risk, at risk,
or being at high risk for the development of CVD. The most current FRS model scores
delineate percentage of risk estimation as low risk (< 6%), moderate risk (≥ 6% and <
10%), moderate-high risk (≥ 10 and < 20%), and high risk (≥20%) (Tattersall, Gangnon,
Karmali, & Keevil, 2012). These percentages estimate the risk of developing a CV event
over the course of the next ten years.
FRS percentages ranged from 0.8% to 15.7% with a mean of 3.2991 (SD=2.53).
Utilizing the percentages delineated above, 100 of the EBP project participants or 92%
were identified as being at low risk, 5 (5%) were considered to be at moderate risk, and
3 (3%) were identified as being at moderate/high risk.
In addition to delineating a risk percentage score for development of a CV event
over the duration of a ten year period of time, the FRS also reports a vascular heart age.
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The vascular heart age compares one’s chronologic age to the age of the heart muscle
taking into consideration various identified risk factors. For example, a 40 year old
woman with multiple CVD risk factors may have a heart age that is equivalent to that of a
65 year old woman without risk factors. The FRS informing of the vascular heart age
compared to the person’s chronologic age provides a tacit mechanism in which to
convey the significance of CVD risk factors to the patient as they relate to the health of
the heart muscle.
Using the laboratory metrics (TC, HDL cholesterol and blood sugar) and gleaned
assessment data (age, smoking, and SBP), the variables were inputted into the FRS
model and heart age was determined. Of the n=109 who completed the laboratory
testing 42% (n=45) had a heart age that exceeded their chronologic age; 1% (n=2) had a
vascular heart age that was equivalent to chronologic age; and 57% (n=62) had a
vascular heart age that was less than their chronologic age. Using BMI instead of
laboratory testing, the variables of age, smoking, SBP, and BMI were entered into the
FRS prediction tool. Of the n=109 EBP project participants, 58% (n=63) had a vascular
age that was greater than their chronologic age; 8% (n=9) had a vascular heart age
equivalent to their chronologic age; and 34% (n=37) had a vascular heart age that was
less than their chronologic age.
If basing clinical decisions on risk level alone, many women would not receive
primary prevention intervention education and strategies to reduce identified modifiable
risk factors. As will be elucidated in the following section, the majority of women did
exhibit modifiable CVD risk factors which were identified through the risk assessment
screening.
Systolic blood pressure, diastolic blood pressure, BMI, smoking, TC, TG, LDL
cholesterol, HDL cholesterol, and blood sugar were the nine modifiable risk factors that
were assessed with the EBP project. Graph 4.2 visually depicts the identified risk factors
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along with the frequency distribution. Graph 4.3 visually correlates each study participant
(n=109) with the number of modifiable risk factors each participant possessed. Only 9%
of the project participants didn’t have identified risk factors and would be considered to
be at ideal CV health as defined by the AHA. 13% had only one identified risk factor;
27% had two identified risk factors; 16% had three identified factors; 16% had four risk
factors; 9% had five risk factors; 7% had six risk factors; 2% had seven risk factors and
only one person (1%) had eight identified risk factors. The significance of the identified
CVD risk factors will be discussed in detail in chapter 5.
Figure 4.2
Modifiable variables and their frequencies
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Figure 4.3
Number of modifiable risk factors and their frequency within the study population n=109

Correlation is a statistical technique that is used to measure and describe the
degree and direction of the linear relationship between two variables (Gravetter &
Wallnau, 2008). In the data analysis that was performed using Pearson’s Correlation
Coefficient (Pearson r) it can be determined if there is a direct correlation between two or
more specific variables. Correlations can be used for a number of applications including
prediction, validity, reliability, and theory verification (Gravetter & Wallnau, 2008). The
correlation coefficient will be between -1.0 and +1.0. Correlations that are above +0.7 or
below -0.7 represent a strong correlation between the tested variables (Cronk, 2010). A
positive correlation indicates that as one variable gets larger, the other variable will also
get larger. Conversely, a negative correlation indicates that as one variable gets larger
the other variable will get smaller (Cronk, 2010). Correlations are reported numerically
as the correlation, the significance, and the n, with degrees of freedom being n -2
(Cronk, 2010). The significant correlations that were gleaned will be delineated below.
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Table 4.3 Correlation Table
______________________________________________________________________________
Variable Correlation

Result

SBP/DBP

r (107) = 0.735, p <0.000

Age/FRS

r (107) = 0.446, p <0.000

SBP/FRS

r (107) = 0.516, p < 0.000

Age/BMI heart age

r (107) = 0.539, p <0.000

SBP/BMI

r (107) = 0.340, p < 0.000

LDL/TC

r (107) =0.892, p < 0.000

LDL/HDL

r (107) = -0.307, p < 0.001

Significance ___
Represents a strong positive
correlation indicating that a
significant positive linear
relationship between the two
variables exist; indicating that
as SBP increases so does DBP
or vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as age increases the
FRS increases or vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as the SBP increases
the FRS increases or vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as age increases so
does BMI heart age or vice
versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as SBP increases so
does BMI or vice versa
Represents a strong positive
correlation indicating a
significant positive linear
relationship between the two
variables; indicating that as
LDL cholesterol increases so
does TC or vice versa
Represents a moderate
negative correlation indicating
a significant negative linear
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DBP/HDL

r (107) = -0.346, p < 0.000

TG/DBP

r (107) = 0.309, p < 0.001

TG/TC

r (107) = 0.357, p < 0.000

TG/HDL

r (107) = -0.474, p <0.000

FRS/DBP

r (107) = 0.486, p < 0.000

FRS/TC

r (107) = 0.473, p <0.000

FRS/HDL

r (107) = -0.305, p <0.000

BMI/SBP

r (107) = 0.340, p <0.000
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relationship between the two
variables; as LDL increases
HDL decreases or vice versa
Represents a moderate
negative correlation indicating
a significant negative linear
relationship between the two
variables; as DBP increases,
HDL decreases or vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as TG’s increase,
DBP also increases or vice
versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as TG increases so
does TC or vice versa
Represents a moderate
negative correlation indicating
a significant negative linear
relationship between the two
variables; therefore as TG
increases HDL decreases or
vice versa
Represents a moderate
positive correlation indicating
a significant linear relationship
between the two variables; as
FRS increases so does DBP or
vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
correlation between the two
variables; as FRS increases so
does TC or vice versa
Represents a moderate
negative correlation indicating
a significant negative linear
relationship between the two
variables; as FRS increases
HDL decreases or vice versa
Represents a moderate
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BMI/DBP

r (107) = 0.334, p <0.000

BMI/HDL

r (107) = -0.398, p <0.000

DBP/FRS

r (107) = 0.486, p <0.000

LDL/FRS

r (107) = 0.513, p <0.000

TG/FRS

r (107) = 0.377, p <0.000

Blood sugar/FRS

r (107) = 0.547, p <0.000

BMI/TG

r (107) = 0.321, p < 0.001

78
positive correlation indicating
a significant positive linear
relationship between the two
variables; as BMI increases
SBP also increases or vice
versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as BMI increases so
does DBP or vice versa
Represents a moderate
negative correlation indicating
a significant negative linear
relationship between the two
variables; as BMI increases,
HDL decreases or vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as DBP increases so
does FRS or vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as LDL increases so
does FRS or vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as TG increases so
does FRS or vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as blood sugar
increases so does the FRS or
vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as BMI increases so
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BMI/blood sugar

r (107) = 0.379, p <0.000

BMI heart age/blood sugar

r (107) = 0.501, p <0.000

BMI heart age/FRS

r (107) = 0.895, p <0.000

BMI/BMI heart age

r (107) = 0.301, p <0.001
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does TG or vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as BMI increases so
does blood sugar or vice versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as BMI heart age
increases so does blood sugar
or vice versa
Represents a strong positive
correlation indicating a
significant positive linear
relationship between the two
variables; as BMI heart age
increases so does FRS or vice
versa
Represents a moderate
positive correlation indicating
a significant positive linear
relationship between the two
variables; as BMI increases so
does the BMI heart age

Statistical analysis of the metrics acquired during the implementation of the EBP
project have identified a cogent number of women who manifest modifiable risk factors
and are therefore at increased risk for the development of CVD. The conundrum exists
for practitioners regarding the interpretation of the data. The FRS has traditionally based
CVD risk on the score percentage which, even with a multiple number of risk factors, still
puts the percentage of having a CV event over the next ten years as being low,
especially in younger women. The most current recommendation of identifying women
as being at optimal risk, at risk, or at high risk may more accurately identify women who
may benefit from lifestyle modification or early intervention. Identifying women as being
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at risk or at high risk will hopefully cause practitioners to be more circumspect in
screening and interpreting CVD risk in women.
The descriptive data analysis and correlation data comparisons provide tangible
conclusions that support the need for a clinical practice change. The PICOT question: In
women ages 35-50 presenting for their annual gynecologic exam, who are asymptomatic
for cardiovascular disease, how does implementation of the FRS model, compared to
usual care (no screening), identify the level of CVD risk over a three month period of
time? was saliently answered with the data analysis. The EBP project identified 91% of
the study participants as having at least one modifiable risk factor for the development of
CVD. The significance of each identified risk factor will be discussed in depth in chapter
5. The standard of care in this clinical practice setting is opportunistic at best, meaning
that a patient may be counseled on an elevated blood pressure, or history of smoking
but all risk factors are not realized or inputted into a risk prediction model such as the
FRS model. Dissemination of the EBP project findings to the administrative practice staff
and medical providers will hopefully modulate a clinical practice change.
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CHAPTER 5
DISCUSSION
Despite progressive advances in our understanding of the determinants of
atherosclerosis, cardiovascular disease (CVD) remains the leading cause of morbidity
and mortality worldwide (Von-Khue, Martin, Blumenthal, & Blaha, 2012). The purpose of
the evidence-based practice (EBP) project was to determine if applying the Framingham
risk score (FRS) model to asymptomatic women would appropriately identify modifiable
risk factors as well as their CVD risk percentage related to the probability of a CV event
over the course of the next ten years. The clinical question to be answered was: In
women ages 35-50 presenting for their annual gynecologic exam, who are asymptomatic
for CVD, how does implementation of the FRS model compared to usual care (no
screening) identify CVD risk over a three month period of time? The major goal of this
primary prevention EBP project was to screen women without disease to identify and
quantify their modifiable CVD risk factors. One of the cornerstones of health is to identify
individuals who have an increased risk of developing an adverse outcome over a
specific period of time so that they can be targeted for early preventive strategies
(Ahmed, Debray, Moons & Riley, 2014).The EBP project implementation site was a large
OB/GYN practice that while espousing to providing comprehensive women’s health care,
was not implementing the recommended ACC/AHA preventive CV screening in their
patient population. The outcomes of the EBP project demonstrate that application of the
FRS model in asymptomatic women succinctly identifies modifiable risk factors and
stratifies level of CVD risk into ideal CV risk, at risk, or at high risk for developing CVD.
This chapter will articulate the EBP project findings from Chapter 4 and discuss the
implications of the findings as they pertain to evidence-based APN clinical practice.
Evaluation of the theoretical frameworks in relationship to this EBP project will be
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conveyed as well as strengths and weaknesses of the EBP project, and implications for
the future.
Explanation of findings
Clinical trials have demonstrated that when CVD modifiable risk factors are
treated and corrected, the chances of developing CVD are significantly reduced
(D’Agostino, Pencina, Massaro, & Coady, 2013). The literature purports that CVD risk is
multifactorial and synergistic over time for development of actualized disease. In order to
potentially prevent CVD, risk factors in individuals without disease must be identified and
quantified. Estimating risk plays an important role in understanding the underlying
mechanisms involved in the etiology and progression of chronic disease and guides
prevention and treatment (Kariuki, Stuart-Shor, & Hayman, 2013). As elucidated in the
literature there are a myriad of risk prediction tools available to assess an asymptomatic
woman’s risk of CVD. The ACC/AHA recommends a Framingham type global risk score
that incorporates multiple traditional CV risk factors for all adult women without a history
of CVD. The most current guidelines promulgated in the literature ascertain that for
patients 20 to 79 years of age who are free from CVD, the first step is to assess for CVD
risk factors (Goff, et al., 2013). CVD risk scores have the potential to educate and inform
patients, motivate them to change their level of risk, and reinforce the importance of
compliance with a plan of care.
Of the 109 women who completed their laboratory testing and who’s data was
evaluated using the FRS models, 91% (n=99) had at least one identified modifiable risk
factor, 27% had two identified risk factors, 16% had three risk factors, 16% had four risk
factors, 9% had five risk factors, 7% had six risk factors, 2% had seven risk factors and
1% of the study participants had eight identified CVD risk factors. As a practicing
clinician, each provider must critically evaluate the risk factors for their significance to the
health of the patient. For example, having a single risk factor of elevated BMI may not
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hold the same health consequence as an individual risk factor of a blood sugar of 300.
Using one’s medical acumen and experience will guide the clinician in determining which
patient needs immediate follow up and which ones can have their identified risk
reviewed and discussed at the next appointment. It was determined from the critical
valuation of the data that 50.5% (n=55) of the study cohort required timely follow up
appointments for statistically significant identified risk factors. Clearly those individuals
with significantly elevated blood sugar, blood pressure and cholesterol levels needed
timely intervention with either lifestyle modification or lifestyle and medication modalities.
The outcomes of the EBP project were correlative to those communicated in the
CV literature using similar OB/GYN practice settings. The American College of
Cardiology Foundation (ACCF) revealed results from a pilot study done in the OB/GYN
setting which identified 69% of the study participants exhibiting significant CV risk (SCAI,
2012). Another study that was implemented in ten different OB/GYN practice sites over a
2 year period of time identified 87% of the study participants with significant CVD risk
factors (Mehran & Yu, 2012).
Correlational statistics using Pearson’s r exhibited twenty seven statistically
significant relational correlations (p<0.001). The two variables being assessed occur
naturally and are not manipulated or controlled by the project manager (Gravetter &
Wallnau, 2008). These correlations were logically anticipated as they related to
modifiable risk factors and how they interact to increase heart age, FRS percentages,
and need for follow up. The results of the data analysis were statistically significant in
both identification of risk factors and correlations between interval data variables.
The single most identified CVD risk factor was BMI, with 76% (n=83) of the EBP
project participants exhibiting a BMI ≥25 kg/m². These statistics from the EBP project are
equivalent to those communicated in the literature. Statistics reported in both general
scientific literature and CV literature confirm that two out of every three adults in the U.S.
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are overweight or obese. There is a linear relationship between increasing BMI and allcause mortality, especially CVD related death (Von-Khue, Martin, Blumenthal, & Blaha,
2012). Each five unit increase in BMI was associated with a 29% increase in mortality in
women (Dudina et al., 2011). This risk factor in isolation may not necessitate an
immediate follow up appointment but it assuredly needs to be addressed at each
subsequent patient appointment. BMI is a formidable risk factor that is also associated
with an increased risk for the development of Type II diabetes, hypertension, and
dyslipidemia, all of which are significant risk factors for CVD.
To reiterate the findings reported in chapter four, the modifiable risk factors
appraised included systolic blood pressure, diastolic blood pressure, total cholesterol,
triglycerides, LDL cholesterol, HDL cholesterol, smoking, and BMI. Diastolic blood
pressure was more significantly elevated than systolic blood pressure with 16% (n=17)
of the study participants having elevated diastolic blood pressures and 6% (n=7) having
elevated systolic blood pressures. All fractions of the lipid panel demonstrated significant
abnormalities, with LDL cholesterol elevation being seen in the greatest number of study
participants. As previously articulated LDL cholesterol has a deleterious effect on CVD
health and is more discerning in the female population. 38% (n=41) of the participants
had elevated total cholesterol, 20% (n=22) had elevated triglycerides, and 58% (n=63)
had elevated LDL cholesterol. According to the study conducted by Ip (2009) greater
than 50% of CV events are due to elevated cholesterol fractions. Elevated blood sugar
of ≥100 was reported in 20% (n=22) of the project participants. Smokers constituted
14.7% (n=16) of the EBP project participants. It was not ascertained the amount of
cigarettes smoked or the duration of smoking history. Cigarette smoking is dose related
and does significantly increase CVD risk in the female population.
The percentage of women who exhibited ideal CV health, as previously outlined
by the AHA, was 9% (n=10) of the EBP project study participants. This is a higher
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percentage than has been reported in the literature. A cohort study of 14515 adults
revealed less than 1% of the participants possessed ideal CV health (Himmelbarb &
Hayman, 2012). The remaining 91% of the EBP project participants were at risk for
development of CVD. The most current recommendations outlined by the American
Heart Association and the American College of Cardiology are to stratify women as
being at ideal CV risk, at risk or at high risk versus reliance on the ten year risk
percentage reported by the older FRS models. As has previously been discussed,
women can exhibit a myriad of risk factors and still remain at a low risk percentage
according to risk prediction models.
Using the laboratory arm of the FRS prediction model, 42% (n=45) of the EBP
project participants had a vascular heart age that was greater than their chronologic age
and using the BMI arm of the FRS model 58% (n=63) of the project participants had a
vascular heart age that was greater than their chronologic age. The rationale behind the
two arms of the prediction model was the belief that many clinical practice settings were
not implementing the laboratory screening but they could at least ascertain a level of risk
from metrics obtained at the time of the patient visit. The vascular heart age is a
persuasive metric to share with patients that seems to really make an impact on their
understanding of how their heart is actually aging while not exhibiting overt symptoms of
CVD.
Descriptive demographics were completed on the n=109 who completed the
laboratory testing as well as the n=39 who consented to participate but did not follow
through with laboratory testing. The two groups were similar in all areas assessed
including age, race, marital status, insurance status, smoking status, and family history
of CVD. These similarities make the results generalizable to the target population.
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Implications for clinical practice
CVD is well suited for application of primary prevention interventions due to it
being common, occurring at a high incidence, that it can be modified by behavior, has a
long latency period, and has a high economic and societal burden (Ashen, 2010). A
practice grounded in evidence-based practice which integrates clinical expertise, patient
history and values, and the best clinical evidence is an essential component of APN
practice (Facchiano & Snyder, 2013). Implementation of EBP promotes high-value
health care including enhancing quality and reliability, improving health outcomes, and
reducing variations in care and cost (Melnyk, Gallagher-Ford, Long and FineoutOverholt, 2014). Utilization of EBP guidelines will ensure current knowledge is being
used to guide cost-effective evidence based treatment options. The role of risk factors in
the causal pathway to CVD provides a strong rationale for assessment and appropriate
risk factor modification (Pearson, 2002).
The most current clinical guidelines provide evidence for control of modifiable risk
factors and use of primary prevention strategies in the clinical practice setting. Reducing
the burden of CVD must be a shared responsibility among all health care providers. No
longer can there be turf war or a non-committal ideology that it is not within the scope of
practice to screen all women for heart disease risk. Screening must be initiated
whenever and wherever the patient presents and the opportunity emerges. This clinical
practice site purports to provide comprehensive care to women, in order to meet that
tenet, it must assess and evaluate for the disease that is the leading cause of death in
women. Clinical practice settings must also adhere to national guidelines that are
authored by leading experts in the field of cardiology.
Based on the achieved EBP project outcomes it is recommended to implement
routine CV risk screening. The significant outcomes of this EBP project may result in like
practices adopting CVD risk screening as part of their routine provision of women’s
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health care. As previously elucidated, a cogent number of women consider their
OB/GYN as their PCP, especially women of childbearing age. Unique to this OB/GYN
practice is that a family nurse practitioner is a member of the medical provider team and
possesses expertise in primary care and management of chronic medical conditions. It is
a logical transition of care for patients with identified CVD risk to be referred to the FNP
within the practice setting for treatment.
Each patient encounter provides a fortuitous opportunity to educate women on
the role of risk factors related to the development of CVD as well as broaden the patients
understanding and knowledge of CV health. After initial assessment of risk, CVD risk
must be reassessed throughout the lifespan. Applying principles of prevention with each
patient encounter will improve health outcomes and reduce health care costs.
Implications for the APN role
The principles of EBP are the cornerstone for APN’s to translate research
findings into clinical practice and provide patients with the best available evidence to
guide their healthcare decisions (Facchiano & Hoffman-Snyder, 2012). In a health care
environment that has expectations of providing expedited care to a more complex
patient population while remaining cognizant of cost containment, APN’s possess the
competence, knowledge, and expertise to empower patients in understanding and
incorporating EBP into their plan of care. As an APN, the ultimate goal of healthcare is to
provide the best care possible to our patients, care that is grounded in research and is
evidence-based. Implementation of EBP strategies may increase patient compliance in
health promoting behaviors and decrease disease burden.
Advance practice nurses play a pivotal role in the primary prevention of CVD in
women. Exhibiting a leadership role in CV health, APN’s may need to challenge the
status quo, lobby for health system reform, motivate and inspire other health
professionals to engage in a shared vision for improving health and well-being in women
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(Lanuza, Davidson, Dunbar, Hughes, & Geest, 2011). According to a study which
surveyed women regarding CVD, only 21% of women reported that their health care
provider had ever discussed their risk for CVD, reinforcing previous findings that health
care providers underestimate CVD risk in women and underuse preventive therapies
(Roberts & Davis, 2013).
Office based CVD risk assessments are essential and cost effective in identifying
modifiable risk factors and should be implemented as a routine part of the
armamentarium of clinical practice. The aim of CVD risk assessment is to be more
effective in identifying those at risk and to facilitate more efficient use of treatment and
prevention resources (Owen & Reid, 2013). This EBP project reinforced evidence
elucidated in the literature that CVD risk screening in women without disease is crucial in
identifying CV risk. A substantially lower lifetime risk of developing CVD occurs among
individuals with optimally controlled risk factors. It is noteworthy that individuals who
reach middle age with optimal levels of all major risk factors have only a 6-8% remaining
lifetime risk of developing CVD (Heidenreich et al., 2011).
The APN must sharpen his/her CVD acumen, infuse evidence into the clinical
practice setting, be able to effectively understand and communicate CVD risk, accurately
administer and interpret risk prediction scores and its implications for the patient, and be
actively involved with the patient in formulating a plan of care that incorporates evidencebased risk prevention strategies. Once screening and risk has been ascertained,
discussion of identified CVD risk factors is prima facie in reversing this devastating
disease. Assisting the patient to understand their risk and facilitate a plan of care, the
APN must utilize a number of educational tools and communication techniques. This is
where the APN can effectively utilize the tenets of the health promotion model (HPM) to
assist the patient in understanding their risk and identify methodologies to reserve that
risk. In conjunction with their patients, APN’s can be instrumental in empowering their
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patients to become proactive with health promotion and disease prevention, inclusive of
CVD. APN’s as transformational leaders influence and engage individuals in a shared
vision and provide innovative methods in which problems are viewed and solved
(Lanuza et al., 2011).
Clinical practice guidelines provide a foundational framework for the APN to
screen their patients for CVD risk. The APN must familiarize herself with the guidelines
and be fastidious in ongoing CVD risk assessment through the lifespan of their female
patients. Using EBP constructs, APN’s can provide evidence and research regarding the
symbiotic interaction of modifiable CVD risk factors and provide evidence based
interventions to change CVD outcomes. According to Roberts and Davis (2013), 44-50%
of the decrease in CVD mortality is related to risk factor reduction related to lifestyle and
environmental changes such as blood pressure, blood sugar, cholesterol, BMI, and
physical activity. APN’s can meld the triad of EBP tenets of evidence, such as clinical
practice guidelines, clinical experience and knowledge, and patient preference to
improve the CV health of women.
Another germane tenet to APN practice is in fostering collegiality among their
peers. The APN is continually being provided a fortuitous opportunity to share
knowledge and expertise. APN’s must remain vigilant in remaining abreast of the most
current evidence and research and must take advantage of every opportunity to be a
conduit to share CV evidence at the professional, individual patient, and population level.
Evaluation of applicability of the theoretical frameworks
The EBP step wise approach assists the practicing APN in identification of a
clinical question precipitating the APN to search for the most current relevant scholarly
evidence as it relates to an identified clinical issue. Critical appraisal of the evidence for
validity, reliability, and applicability to practice is essential for integration of the evidence
into clinical practice (Melnyk, Gallagher-Ford, Long, Fineout-Overholt, 2014). If a
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practice change is implemented based on the EBP process, it will be incumbent to
disseminate the evidence and foster an environment that is conducive for change. In
order for the EBP project to become a permanent paradigm shift in clinical practice there
must be continuous monitoring and ongoing evaluation of the EBP change.
The five phases of the Stetler model for EBP were used as the underpinning to
facilitate progression of the EBP project. The model outlines a number of critical thinking
and decision making steps to assist the DNP student in effectively implementing an EBP
project. Stetler’s model de-emphasizes practice based on tradition and instead stresses
use of research findings as well as other sources of credible information (Stetler, 2001).
This foundational framework was inclusive of: a) preparation; b) validation;
c) comparative evaluation and decision making; d) translation and application; and
e) evaluation (Ciliska et al., 2011). This framework was an appropriate fit and was used
successfully to promote, design, implement, and evaluate the EBP project.
In the preparatory phase of the model, the clinical question is identified and
formulated for its potential influence in clinical practice. Affirmation of the clinical
question as a clinical priority was ascertained. Women’s cardiovascular health has been
touted as a health priority in this practice setting for many years but implementation of
risk prediction screening had never come to fruition. It was imperative during this phase
of the process to examine both external and internal factors that may exert influence in
the EBP project. A critical and exhaustive search of the evidence reinforced the
necessity for screening asymptomatic women for CVD risk. The relevant literature
provided credence to the significance of the EBP project and mitigated the development
of expected outcomes and goals. The PICOT question was formulated and defined.
Phase two of the Stetler model assisted the EBP project manager in critical
appraisal and grading of the evidence that was garnered during the first phase. The
appraised literature revealed an appropriate number of high level evidence studies.
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Several appraisal tools were utilized in the evaluation of the evidence including the
AGREE II, CASP, and Melnyk & Fineout-Overholt’s (2011) rapid appraisal checklist.
Assimilation of the evidence resulted in 20 articles that were included in the evidence
table. The evidence was inclusive of 14 Level I evidence studies, four Level IV evidence
studies, and two Level VI evidence studies.
Phase three of the EBP model had the project manager analyzing and coalescing
the evidence for the best clinical practice fit. Involvement of the management staff, CEO,
and marketing director as influential stakeholders were included in the dissemination of
evidence supporting the need for and expected outcomes of the EBP project. A decision
regarding the risk prediction tool, format for implementation, as well as expected
outcomes were based on the appraisal of the evidence.
In phase four of the model, implementation; the project manager designed the 12
week primary prevention intervention based on the significance of the clinical issue and
the identified need for a clinical practice change. IRB approval was obtained from
Valparaiso University and the process for the EBP project implementation was
presented to and approved by the CEO and management team of the clinical practice
site. Education was completed with the medical office staff, the nursing staff, and the
administrative staff at the implementation site. Education was rendered via power point
presentations, scripted modules, role playing, and question and answer time.
The fifth and final phase of the Stetler model was to amalgamate the statistical
data and promulgate the findings. Change strategies were evaluated and implemented
in preparation for a clinical practice change. Critical evaluation of the entire EBP process
was completed by the EBP project manager including strengths and weaknesses of the
project, use of the theoretical frameworks, and implications for clinical practice. These
tenets will be expounded upon in the following sections.
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According to the 2012 AHA National Survey by Mosca and colleagues, women
engaged in preventive behaviors to improve their health and feel better, not to live longer
(Roberts & Davis, 2013). Thirty five percent of the women surveyed by Mosca and
colleagues reported that they had no barriers to engaging in preventive behaviors and
felt they lived a heart healthy lifestyle. In the remaining sixty five percent, lack of time,
family obligations, lack of financial resources, and lack of confidence in their ability to
achieve behavior change were cited as barriers to a heart healthy lifestyle (Roberts &
Davis, 2013). Once risk is estimated, understanding and communicating risk is
acknowledged as being a daunting task. Practitioners must be cognizant of a myriad of
interpretations as to what constitutes health and health promoting behaviors and what
influences affect each individual patient. Practitioners must be mindful that self-esteem,
societal support, social status, family values and views, as well as one’s own personal
control over their health all interact in health promotion. Acknowledgement by women
that CVD is the leading cause of death in their gender will support the impetus for
primary prevention and identification of modifiable risk factors and ultimately empower
women to become proactive in their health. The APN ideally wants to instill CVD
prevention strategies in patients with the ultimate intent of preventing negative health
outcomes.
Pender’s health promotion model (HPM) served as an excellent foundational
nursing model for this EBP project cohort to actively participate in health promoting
behaviors. The components of the model lead to a logical progression of the concepts
needed to improve health and health behaviors and support the belief that health
behaviors must be in control of the patient and have meaning to the patient in order to
be effective (Bennett, Perry & Lawrence, 2009). The HPM can be used to increase
perception of CVD risk and facilitate conversation regarding health beliefs and
behaviors. Implementing the HPM can serve as a conduit to change health from a
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paradigm of disease management to one of health promotion and disease prevention.
APN’s must be creative and innovative in developing strategies that will break down
identified barriers and allow patients to participate and be proactive in a heart healthy
lifestyle. The HPM adequately pulls together the factors that can motivate and engage
the patient in establishing and monitoring goals and increase adherence to positive
health behaviors.
Strengths of the EBP project
The fundamental tenet to successful implementation of EBP resides in an
organizational culture that finds value in EBP and is supportive of EBP implementation.
The main strength of this EBP project was a practice environment that supported the
EBP project and a supportive provider and administrative staff who collaborated with the
EBP project manager in navigating the project implementation. The DNP project
manager provided credibility for the EBP through extensive research and critical
appraisal of the CVD literature. The project manager articulated the significance and
background of the project, the scientific evidence to support the EBP, the tool to be
implemented, and the expected outcomes of the EBP project to the key stakeholders.
The relevance of the health issue as a health priority, the amount of evidence supporting
the health priority, and the ease with which the EBP project can be replicated enhanced
the strength of the project. Critically evaluating the EBP throughout the implementation
phase supported the implications that the EBP project had to practice issues, research,
theory, and education. The EBP project goals and objectives were in alignment with the
vision and mission of the clinical practice setting. The foundational basis of the EBP
project using the Stetler model and the HBM provided a sound theoretical framework
from which to develop, implement, and evaluate the EBP project.
Ease of implementation of the EBP project into the clinical practice site was an
identified strength. There was minimal interruption of normal work flow by the clinical or
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provider staff. The clinical staff felt well educated on the implementation process and
was enthusiastic and comfortable in identifying potential study participants, educating
them, and obtaining informed consent. There were no overtime hours needed for
implementation of the EBP project and the associated costs were miniscule, mainly
consisting of nominal office supplies.
The literature is saturated with studies validating the reliability and usefulness of
the FRS model as a gold standard CVD risk prediction tool. The tool was easily
implemented into the clinical practice site and inputting of metrics into the web-based
program provided a quick analysis of the variables and rapid reporting of the findings.
The ability of being able to scan the reports into the patients EMR provided accessibility
for all providers to view the FRS results at any point along the continuum of care. As part
of this EBP project, the project participants were sent thank you letters, applauding them
for being proactive in their heart health, and were provided with copies of their FRS
results along with an explanation of the findings. Providing the patient with a tangible
visual result reinforced the findings and provided a mechanism for the patient to evaluate
their results without the time constraints of an office appointment. Another identified
strength of the FRS tool is its reporting and explanation of heart age which provided in
layman terms how the individuals’ heart was aging. Vascular heart age is intuitively an
easily understood way of illustrating the likely reduction in life expectancy if risk factors
are not reduced.
Utilizing the EMR to calculate risk automatically will become the mainstream of
current and future risk algorithms (Goff et al., 2013). Using the EMR as a method for all
members of the health care team to review the results of the risk screening and to alert
the practitioner of when screening needs to be redone will aide in the ongoing diligence
of continued implementation of this EBP practice change and well as pervasive
awareness to CV health.
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Limitations of the EBP project
Implementation in only one of five clinical practice settings was a limitation that
was identified with the EBP project. Since this OB/GYN practice has several locations
around the geographical area, the demographics will vary to a certain extent. For
example, the demographic of the EBP project implementation site consisted of
approximately 65% commercially insured patients, 25% Medicaid, 6% Medicare and 4%
uninsured while our inner city clinical practice site is composed of approximately 60%
Medicaid patients, 20% commercially insured, 5% Medicare, and 15% uninsured. Once
the EBP project becomes a permanent clinical practice change, women at all clinical
sites will be offered and screened for CVD risk.
The EBP project sample was a convenience sample of women and therefore may
exhibit participation bias. Many studies have demonstrated that those who volunteer for
screening may be healthier than the general population (Gordis, 2009). Another potential
bias may be identification of those in the pre-clinical phase versus those close to
exhibiting overt disease. Because CVD has a long prodromal phase, younger patients
may be healthier than those who are older and possibly closer to exhibiting overt
disease therefore exhibiting various degrees of risk. The longer the preclinical phase, the
more likely the screening program is to detect the case while it is still preclinical (Gordis,
2009). Attrition is a concern while implementing any type of research or EBP. Originally
148 women signed the consent form to participate in the EBP but 109 actually
completed the laboratory portion of the project for a participation rate of 73.6%.
Demographics were compared between the two groups and demonstrated that they
were comparable in all areas of demographics.
There are limitations to any of the risk prediction models, namely that they are
most effective within the population from which they were derived and the
outcomes/end- points that they attempt to address. The literature identifies over one

SCREENING CARDIOVASCULAR RISK

96

hundred CVD risk prediction models. No one model assesses all of the variables that
have been associated with CVD risk. The question can be posed if a different tool would
yield a different result within the same sample population. However, as has been
previously articulated, the risk prediction tool must effectively assess multivariate CVD
risk but be cost-effective and be easily implemented in the clinical practice setting.
Regardless of the tool, the general principal remains the same, namely to accurately
predict the risk of future occurrence of an outcome in an individual utilizing the values of
multiple characteristics (Ahmed, Debray, Moons, & Riley, 2014). One of the major
limitations of the FRS model articulated in the literature is its potential for underestimating risk, especially in younger populations. However the FRS remains a gold
standard tool for use in the clinical setting to identify and stratify CVD risk.
Implementation of the Framingham risk predictive tool identifies CVD risk and allows the
practicing clinician to implement further EBP prevention guidelines or refer the patient to
another clinician for further assessment and/or treatment.
Another limitation of risk prediction models is that many of them are neither gender
nor ethnically specific and therefore may not be representative of the general population.
This is especially poignant in minority populations who historically have a
disproportionate risk for CVD. Fortunately the FRS model does predict gender specific
levels of risk but is not ethnicity specific scores. CVD risk and health outcomes are
influenced by environmental, social, economic, and biologic factors (Lanuza et al., 2011)
which are not reflected in our current risk predictive tools.
Another limitation to the risk prediction models is in their definition of risk level. It is
discerning the magnitude of risk factors exhibited by women, especially those under the
age of 50, who still do not reach a high percentage of CVD risk as defined by some risk
prediction models. It is certainly more prudent to follow the tenets as outlined by the
ACC/AHA, which is to define women as being at ideal risk, at risk, or at high risk for
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development of CVD. The various delineations of risk levels can be confounding for the
practicing clinician and is often a cited reason for not implementing risk screening in the
clinical setting. A standardization of values and tools would allow for greater ease of
implementation.
Barriers to implementation of EBP in the clinical setting are many and may include
time constraints, organizational culture and philosophy, inadequate EBP knowledge, lack
of access to databases for evidence searching, leader resistance, work load, and limited
access to resources that facilitate EBP (Melnyk, Gallagher-Ford, Long, & FineoutOverholt, 2014). Other barriers may include lack of reimbursement for preventive care,
lack of incentives to practice primary prevention, lack of understanding and skill at
implementing the various risk prediction models, and lack of understanding in
interpreting and communicating the findings. Barriers to implementation may also come
from the patients themselves who may be reticent to screening or implementing lifestyle
changes. Change strategies must be implemented within the clinical setting to eradicate
barriers to EBP.
Implications for the future
Practice. Strategies for implementation and sustainability of EBP need to be
multi-faceted to include education and knowledge enhancement, cultivation of an
organizational culture of EBP, development of EBP leaders and mentors, resource
availability, expectation of initiating an EBP environment, and recognition for
engagement in EBP (Melnyk, Gallagher-Ford, Long, & Fineout-Overholt, 2014). The
intended effect of EBP is to standardize healthcare practices to science and best
evidence and to reduce illogical variation in care, which is known to produce
unpredictable health outcomes (Quigley, Huston, & Covell, 2013). Aligning with the
recommendations from the Institute of Medicine and providing quality of care, EBP
unifies research evidence with clinical expertise and encourages individualization of care
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through inclusion of patient preferences (Quigley, Huston, & Covell, 2013). Combining
national guideline recommendations or pathways backed by current research, APN’s will
consistently be providing comprehensive evidence-based care to their patients.
Since the first screening guidelines for screening women for CVD risk were
published in 1999, there continues to be a pervasive disconnect between nationally
recommended CVD risk screening and implementation of guidelines in clinical practice.
According to Perk (2012), 62% of physicians used subjective assessments to gauge CV
risk rather than employ a risk calculator. Approximately 60% of PCP’s and OB/GYN’s
state that they were aware of the ACC/AHA evidence-based CVD screening guidelines
yet only 39% of PCP’s and 21% of OB/GYN’s reported incorporating the guidelines into
clinical practice (Wells & Kalman, 2011). This is reflected within the EBP project
implementation site, no consistent CVD risk screening was being done. Debate
continues as to who is responsibility to initiate screening, is the responsibility of only the
PCP or should anyone who interacts with the patient take the initiative to institute CVD
risk screening? Death rates for women 35 to 54 years of age are trending upward,
compared with the previous four decades (Carey & Gray, 2012). Unless the
determinants of CVD risk are identified and reversed, CVD rates in women will continue
to trend upward. Unfortunately, OB/GYN practitioners were reported to substantially
have less awareness of national CVD screening guidelines than other medical
practitioners (Carey & Gray, 2012). The commonly held belief that OB/GYN practices
focus only on reproductive and breast health must be reversed and this clinical specialty
must place emphasis on comprehensive women’s health care including screening for
CVD risk.
The outcomes of the EBP project demonstrated its effectiveness in identifying
CVD risk in asymptomatic women. Implementing CVD risk assessment screening in this
clinical practice setting requires an educational protocol and a referral process for
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patients with identified high levels of risk. The clinical practice site used for
implementation of this EBP project is in the process of looking to partner with an internal
medicine or cardiology practice in an effort to provide a seamless system for the patient
and improve transitions in care. Utilizing the EMR provides a straight forward method to
view CVD risk screening results, track risk screening dates, and to alert the practitioner
as to when CVD risk screening needs to be redone.
Theory. The theoretical frameworks that served as a guide for this EBP were
applicable and effective throughout the EBP process. An interesting article published in
the NEJM (2014) found that women often viewed their risk or development of CVD as
the consequence of having done something bad; that it was essentially their fault
whereas cancer was something bad that happened to them but not caused by them.
Future theory development or application of current theory should focus on this
perception of risk and work to expand knowledge regarding CVD and its associated risk
factors.
As the first estimation of risk for CVD, calculating the FRS is clinically helpful in
identification of individuals at high or low risk, however those at intermediate risk may
need further risk stratification with additional testing. If risk is identified, additional testing
could be performed such as lipoprotein subfractions, CRP-hs, or imaging modalities.
There are a myriad of theoretical models that can be applied by the APN in
clinical practice. Nursing theories must be continually applied to future research
endeavors to assess their validity and applicability to practice issues. Use of the HPM is
applicable to this EBP project and population because once risk is identified, it is
imperative to find the impetus for the patient to make changes in their health behavior to
reverse the identified risk.
Research. For risk prediction models to become common place in clinical
practice, research needs to show that they consistently have a positive impact on health
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outcomes (Ahmed, Debray, Moons, & Riley, 2014). Additional research needs to be
rendered to determine the role and inter- relatedness of all associated CVD risk factors.
Research needs to demonstrate that identified level of risk is indeed associated with
development of disease and if the level of risk is decreased, that there a commensurate
decrease in disease development. Additional research needs to be executed regarding
significance of identified risk factors as they relate to a younger population. This EBP
project assessed women 35-50 for early identification of CV risk; however the literature
is unmistakable regarding increased rates of obesity and type II diabetes manifesting in
younger individuals, even children. This discerning data trend will cause an increase in
CVD among younger individuals and research must focus on assessment and
interventions for this younger age group.
Although there are over one hundred CVD risk prediction models reported in the
literature, there is currently not one tool that evaluates all identified CVD risk factors as
they relate to women. As articulated in chapter two, evidence is informed in the literature
on risk factors such as family history, LDL cholesterol, diet, and physical activity which
are not reflected in the FRS model, yet are consequential in the development of CVD.
Future research endeavors must focus on the role of all identified CVD risk factors and
focus on identification of which variables are the most important for risk prediction.
Although the FRS model is gender specific, is validated and reliable in the U.S.
population, and is a recommendation in clinical practice guidelines, is does not
encompass all risk factors that play a pivotal role in the development of CVD in women
nor is it ethnically diverse. Research is ongoing with new risk prediction models that will
add additional variables as well as genetic markers which may enhance the
determination of risk prediction outcomes. Addressing risk factors suspected as being
more significant in the female gender may also be ponderous for future research
endeavors. For example, CPR-hs may add prognostic information for a woman’s
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development of CVD. Sharma and Gulati (2013) report on a study where women with
elevated CRP-hs had almost twice the risk of future CV events than those with normal
CRP-hs. Women with history of pre-eclampsia have double the risk of subsequent
ischemic heart disease, stroke, and venous thrombotic events (Sharma & Gulati, 2013)
making this a crucial component of comprehensive patient history taking and an area for
continued research.
Additionally, research must continue on the cost effectiveness of early screening
and intervention. Targeted research must include assessment across ethnic and
culturally diverse groups. It is elucidated in the literature that African American women
and Hispanic women have a disproportionately higher rate of CVD than Caucasian
women, with Hispanic women exhibiting overt CVD ten years earlier than Caucasian
women (Ahmed, Debray, Moons, & Riley, 2014). Healthcare that is designed to prevent
illness and minimize progression of disease is imperative to improve quality of life and
decrease healthcare costs.
Education. The prevalence of CVD will increase by approximately 10% in the
next 20 years under status quo CVD prevention while treatment trends and direct costs
related to CVD will increase three fold (Himmelfarb & Hayman, 2012). Cardiovascular
disease education must be approached from a myriad of perspectives. Continuing to
update the medical providers and office staff on the most current CV literature and
research will keep them apprised of the most up to date information regarding CV health
and trending. Remaining active in professional organizations and sharing expertise and
knowledge with colleagues is imperative to increase awareness of CVD. CV education
must also be approached from both an individual and population or community level.
Each patient encounter provides an opportunity to assess lifestyle behaviors and allows
meaningful interaction on the consequences of poor lifestyle choices. Primary prevention
education must be succinct and continuous to educate the individual and effect change
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in behavior. Being actively involved in population awareness endeavors will expand the
knowledge of CVD within the community. Being active politically with professional
organizations and in policy reform will expand awareness of primary prevention
strategies. Prevention initiatives at the population level such as lifestyle education, stress
reduction, physical activity education, school lunch program changes, senior education,
and smoking cessation will aid in the reversal of CVD. Participating in community health
fairs and community educational forums and health talks allows the practitioner to share
their cardiovascular knowledge and expertise.
The results of this DNP EBP project identified a significant number of women
with undiagnosed CVD risk factors. Having a penchant for prevention, had this project
not been implemented, these women would not have been identified as being at risk for
the development of CVD. Only through early identification of risk can the trajectory of
CVD be reversed. The correlational relationships were expected, if there was a
significantly elevated blood sugar, blood pressure, or lipid panel, there was a
commensurate increase in risk percentage and vascular heart age. The vascular heart
age was the strongest motivating factor for women to verbalize a desire to make lifestyle
changes. Risk percentages had little effect on the patient understanding of their risk, but
a visual depiction of how their heart was aging was eye opening for many of the patients.
Even the other medical practitioners in the practice found the vascular heart age an
interesting tenet and something the patient could understand and relate to. My fellow
colleagues have found the results of the EBP project extremely informative and concur
that this practice setting is an ideal clinical site for early screening and identification of
CVD risk factors and has the potential to appropriately prognosticate and to increase
awareness, education and prevention related to CV health. Implementation of CVD risk
screening in this OB/GYN setting sets us apart from the practice of other OB/GYN
settings and strengthens our commitment to our mission and vision statements. The

SCREENING CARDIOVASCULAR RISK

103

results of the EBP project provide compelling evidence for making CVD risk screening a
permanent practice change.
Conclusion
For a woman to reduce her CV risk, she first has to believe it exists (Rosenbaum,
2014). It is well recognized in the cardiovascular literature that a need exists for a risk
assessment approach that can easily be utilized by medical providers in the clinical
practice setting. Cardiovascular disease has a long latency period therefore the greatest
benefit would be achieved by effective early primary prevention. The deleterious impact
of CVD in women is largely related to modifiable CVD risk factors. Risk factor
modification is tightly linked to knowledge of heart disease and use of preventive actions
by women who are at risk (Roberts & Davis, 2013).
Despite progressive advances in our understanding of the determinants of CVD,
it remains the leading cause of morbidity and mortality worldwide (Van-Khue, Martin,
Blumenthal, & Blaha, 2012). By 2030, it is predicted that more than 40% of Americans
will have some form of heart disease with associated economic costs increasing from
$273 billion in 2008 to $818 billion in 2030 (Facchiano & Hoffman-Snyder, 2012). As has
been repeatedly elucidated throughout this paper, the literature is salient in identifying
80-90% of CVD risk as being preventable. The statistical findings from this EBP project
support the findings reported in the literature, 91% of the study participants exhibited at
least one CVD risk factor with 50.5% exhibiting three or more risk factors necessitating a
timely follow up appointment. The most poignant outcome of the EBP project is the
salient number of women who were previously undiagnosed with CVD risk but now have
had their CV risk identified.
The reality exists that CVD is expected to escalate because of the aging
population, obesity, metabolic syndrome, and diabetes which are all health issues that
affect women disproportionately (Carey & Gray, 2012). Many U.S. women consider their
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gynecologist as their PCP and as such, practitioners in this clinical setting must strive to
provide screening to their patient population.
Implementing the methodology of the EBP process, this EBP project succinctly
identified a clinical issue, critically appraised the literature, identified best practice
recommendation and in a logical methodological approach applied the steps of the EBP
to the clinical question. The resultant analysis of the data provided tacit evidence that
supported the significance of the identified clinical question and provided outcomes that
support the need for CVD risk screening to become a permanent clinical practice
change.
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Appendix A: Data Collection Form
Screening Cardiovascular Risk

Name______________________________________
Age________________________________________
Race_______________________________________
Family history of heart disease in first degree relative before the age of 55 Yes or No
Smoker Yes or No
Blood pressure_______________________________
BMI________________________________________
Blood glucose________________________________
Total cholesterol______________________________
LDL_________________________________________
Triglycerides_________________________________
HDL________________________________________
FRS level of risk_______________________________
Heart age____________________________________
Follow up appointment Yes or No
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Appendix B: Consent form
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Appendix C: Thank you letter for normal results
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Appendix D: Thank you letter for abnormal results requiring follow up appointment
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Appendix E: Thank you letter, abnormal BMI
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Appendix F: Framingham risk score results based on laboratory testing

From The Framingham Heart Study
General CVD Risk Prediction

Risk Factor
Sex
Age
Systolic Blood Pressure
Treatment for Hypertension
Smoking
Diabetes
HDL
Total Cholesterol

Your 10-Year Risk
(The risk score shown is derived on the basis of an equation. Other
print products, use a point-based system to calculate a risk score that
approximates the equation-based one.)
Your Heart/Vascular Age

Enter Values Here

Units

(Type Over Placeholder
Values in Each Cell)

male (m) or female (f)
years
mmHg
yes (y) or no (n)
yes (y) or no (n)
yes (y) or no (n)
mg/dL
mg/dL

f
38
148.0
n
y
n
36
212

8.4%

68
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Appendix G: Framingham risk score results based on BMI

From The Framingham Heart Study
General CVD Risk Prediction

Risk Factor
Sex
Age
Systolic Blood Pressure
Treatment for Hypertension
Smoking
Diabetes
Body Mass Index

Your 10-Year Risk
(The risk score shown is derived on the basis of an equation. Other print
products, use a point-based system to calculate a risk score that
approximates the equation-based one.)
Your Heart/Vascular Age

Enter Values Here

Units

(Type Over Placeholder
Values in Each Cell)

male (m) or female
(f)
years
mmHg
yes (y) or no (n)
yes (y) or no (n)
yes (y) or no (n)
kg/m²

f
38
148.0
n
y
n
38.86

7.8%

63

